Main programme
Scientific programme sponsor
Cellular Pathology
Tissue recognition programme - introduction
Upper and lower GI including endocrine
Gynaecological case studies
Skin case studies
Fluid, Respiratory, Urology case studies
Breast case studies
Silver stains - shining throughout the years
Disease models and quantitative pathology in liver research
Disease models and quantitative pathology in liver research
Cellular Pathology
Learning outcomes
This talk will:
- Introduce exemplar translational models of chronic liver disease, primary liver cancer, and liver regeneration that are used to understand their cellular and molecular basis and develop therapeutics.
- Describe emerging quantitative pathology methods that capitalise on the availability of whole-slide imaging and open-source tools for image analysis of tissue from translational models.
- Discuss the potential application of similar digital pathology methods in both clinical trials and routine diagnostic work.
Sponsored by Cirdan
Speakers
Dr Tim Kendall
Case studies - lung carcinoma & cholangitis
Case studies - lung carcinoma & cholangitis
Cellular Pathology
Learning outcomes
Delegates attending this presentation will gain through the presentation of case studies:
- An insight into clinical context around investigative techniques.
- The challenges encountered.
- The techniques used by the department and the patient outcomes.
- Reinforcement of the concept that the patient is at the centre of everything the laboratory does.
Abstract
Lung carcinoma
Lung carcinoma is the 3rd most commonly diagnosed cancer in the UK and the 2nd most diagnosed cancer worldwide. Pathological diagnosis of non-small and small cell lung carcinoma is essential to ensure patients have access to suitable palliative care and benefit of tailored target therapy.
This presentation discusses the investigative techniques used to differentiate between non-small and small cell carcinoma and the importance of subtyping non-small in order for patients to avail of molecular testing and access the most suitable treatment pathway.
Cholangitis
Patients with autoimmune liver disease regularly display similar clinical diagnostic features for more than one condition. Primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH) are two cohorts of autoimmune liver disease that rely on the collective findings from laboratory serology markers, liver histology and radiological imaging to determine a diagnosis.
In this presentation, it reports the case of a liver biopsy of a female that was suggestive for autoimmune hepatitis. However, the histological pattern was in favour for and reported as primary sclerosing cholangitis.
Sponsored by Cirdan
Speakers
Maria Cunningham
Case studies - LLETZ and gallbladder
Case studies - LLETZ and gallbladder
Cellular Pathology
Learning outcomes
Delegates attending this presentation will gain through the presentation of case studies:
- An insight into clinical context around investigative techniques.
- The challenges encountered.
- The techniques used by the department and the patient outcomes.
- Reinforcement of the concept that the patient is at the centre of everything the laboratory does.
Abstract
Case study 1
Gall bladder The patient presented to their GP with upper abdominal pain in January 2018 after presenting with pain to A&E in February 2018 a series of investigations were performed, the patient was treated for peritonitis and gall stones were identified as the source of the pain. In March 2018 the patient’s gall bladder was removed and sent to the histopathology laboratory at Calderdale Royal Hospital. It was dissected as per laboratory protocols, these were all processed in 1 cassette.
A H&E stained section/slide was produced the following day and the specimen was subsequently diagnosed by the consultant histopathologist as cholelithiasis. No further ancillary tests or immunohistochemistry were required. It was noted at dissection that there was disruption to the gall bladder wall, likely as a result of gallstones. This was not seen on CT and likely contributed to the peritonitis. The patient was discharged and no follow up was required.
Case study 2
Cervical Large Loop excision of the transformation zone (LLETZ) Patient attended a routine cervical screening procedure in March 2018, this was overdue by 3 years due to a recent pregnancy and missing a screening recall test. The cervical screening showed severe dyskaryosis. The patient attended an outpatients appointment in April 2018 at the colposcopy clinic for subsequent examination and treatment. A LLETZ was performed and the specimen was sent to the histopathology laboratory. The specimen was dissected as per laboratory protocols, and both ends of the LLETZ were placed cut side down.
A H&E stained section/slide was produced from each block the following day and the consultant histopathologist diagnosed the specimen from the H&E as high grade CIN, which extended to the margins. This diagnosis was consistent with the results of the cervical screening. The patient was discharged via a letter and the treatment complete, the patient was advised to have a test for cure (cytology and high risk HPV test) at their GP surgery in 6 months time.
Sponsored by Cirdan
Speakers
Jemma Morris
Best practice - andrology
Best practice - andrology
Cellular Pathology
Learning outcomes
Delegates attending this presentation will learn about:
- Equipment verification
- Acceptance testing and traceability of consumables
- Sample collection and receipt
- Quality control
- Changes to methodology.
Sponsored by Cirdan
Speakers
Dave Sanders
Consultant scientist reporting – 2 years on
Consultant scientist reporting – 2 years on
Cellular Pathology
Learning outcomes
Delegates attending this presentation will learn about:
- Career path (and qualifications) to get to consultant post.
- The challenges encountered.
- The contribution of this role to healthcare delivery
- The support available for those wishing to follow in her footsteps.
The main aim is to provide inspiration to others who might wish to embark on advanced practice.
Sponsored by Cirdan
Genomic testing in histopathology: An ethical perspective
Instrumentation – friend or foe?
Instrumentation – friend or foe?
Cellular Pathology
Learning outcomes
The delegates will understand:
- The history, impact and development of instrumentation in Cellular Pathology
- The part of instrumentation in pathology modernisation.
- Compliance with ISO 15189 guidance
- The impact on the knowledge and skill base.
Abstract
The session will look at the core Histology process and the instrumentation used in it its delivery, in doing so we will consider:
- The history, impact and development of instrumentation in Cellular Pathology
- The part of instrumentation in pathology modernisation.
- The effect of technological developments on quality.
- Compliance with ISO 15189 guidance
- The impact on the knowledge and skill base.
Sponsored by Cirdan
Speakers
Rob Hughes
Digital pathology – pilot to practice
Digital pathology – pilot to practice
Cellular Pathology
Abstract
The adventure of implementing a digital pathology system across an entire region told through the numbers; 1 Cancer Alliance, 6 STPs, 7 Project managers, 12 Trusts, 100,000 emails and 2.5 million whole slide images.
Based on the shared experiences of Biomedical Scientists, Project Managers, Procurement specialists and administrators this session will provide advice on how to implement a digital pathology system across a region. It will also provide many examples of how not to implement a digital pathology system, which is probably more helpful.
Sponsored by Cirdan
Speakers
Will Davies
Digital pathology – to infinity and beyond
Digital pathology – to infinity and beyond
Cellular Pathology
Abstract
Digital pathology is increasingly becoming established in the UK due to significant investment from the UK government. In part this is due to the promises of improved pathways and the potential of AI to support diagnosis. This growth in itself poses challenges for translation and adoption for the current technologies, but the current technology is only the tip of the iceberg and many new and emerging technologies are being developed that may have the potential to continue the digital journey.
This presentation will outline some of the current challenges for digital pathology and take a speculative look at some of the future technologies that are being developed and the potentials they may unlock.
Sponsored by Cirdan
Speakers
Dr David Brettle
Immunohistochemistry (IHC) in breast pathology
Immunohistochemistry (IHC) in breast pathology
Cellular Pathology
Learning outcomes
Delegates attending this presentation will learn about the:
- best IHC to use for breast cancer.
- appearances and further molecular testing.
Abstract
Immunohistochemistry (IHC) plays a vital role in breast pathology. With a focus on breast cancer, this presentation will highlight the major role IHC plays when used as a diagnostic aid in breast pathology as well it’s utilisation in predicting response to therapy and prognosis.
With a closer look at current testing strategies this presentation will look at companion diagnostic testing in the past, present and future and fundamentally the importance of accuracy in our diagnostic testing and maintaining quality control.
Sponsored by Cirdan
Lymphoma pathology: The impact of immunohistochemistry, past and present
Lymphoma pathology: The impact of immunohistochemistry, past and present
Cellular Pathology
Abstract
The presentation will be centred in the new markers in Lymphoma diagnosis, in light of the recent molecular discoveries on the pathogenesis of the disease. Also new usages for “old” antibodies will be covered. A special mention to mutation specific antibodies will be included.
The possibilities of scanned slide image analysis in multiplexing markers are also reviewed.
Sponsored by Cirdan
Head and neck pathology: A new module from UK NEQAS for ICC & ISH
Clinical aspects of head and neck pathology
Clinical aspects of head and neck pathology
Cellular Pathology
Abstract
The presentation will cover aspects of the diagnosis and management of complex Head and Neck tumours.
The aim is to provide an overview of the approach to management of these rare lesions and to discuss new developments in diagnostics and treatment.
Sponsored by Cirdan
Recent advances in immunocytochemistry for melanoma diagnosis
Recent advances in immunocytochemistry for melanoma diagnosis
Cellular Pathology
Learning outcomes
Delegates will be given an overview of:
- The growing applications of new antibodies to assist with the diagnosis of malignant melanoma.
- An appreciation of where these new antibodies are likely to be used in the developing field of patient tailored therapeutics.
- An appreciation of the complementary role of histopathology, immunocytochemistry and molecular biology in modern day cellular pathology.
Abstract
Malignant melanoma (MM) remains the deadliest form of skin cancer. It is well known that MM can be treated with surgery alone and survival rates are high, however after metastasis survival rates drop significantly. In histopathological interpretation morphological assessment of any melanocytic lesion is always key, but recent developments within the field of immunocytochemistry (IHC) have provided great support in aiding the distinction of the dysplastic verses malignant lesions. This does not just apply to the diagnosis, but also more recently in providing information regarding prognosis and determining patient therapeutics.
Unfortunately, at present these therapeutic regimes are often short term. As a result, new biomarkers and drug targets are constantly needed in order to develop and improve the accuracy of diagnosis and treatment.
In this presentation we will review the popularly used diagnostic markers (eg MelanA/Mart-1, HMB 45, MITFP, Tyrosinase), as well as also focus on the new markers employed (eg Sox10, PRAME, P16, Ki67) and include options for double labelling techniques too. We will consider the new wave of biomarkers employed to assess therapeutic target treatment regimens (eg BRAF and PD-1) and see how these new approaches are paving the way for new strategies in order to develop a more tailored approach to treatment modalities.
We are beginning to understand the underlying mechanisms of the disease, including melanogenesis, and also how melanomas evade the immune system. IHC continues to play its part in the field; although both useful in diagnosis and prognosis, there is a need to standardise the subjectivity of interpretation of IHC to ensure reproducibility and consistency between laboratories and also between pathologists. This becomes increasingly important as new biomarkers are found and assessed employing the evolution of digital technology.
Sponsored by Cirdan
Speakers
Dr Guy Orchard
Cellular Pathology in sub-Saharan developing Africa – to share and learn
Cellular Pathology in sub-Saharan developing Africa – to share and learn
Cellular Pathology
Learning outcomes
Delegates will learn:
- The position of diagnostic cellular pathology in several Sub Saharan developing African nations when compared to the developed United Kingdom service.
- What knowledge do we have to share.
- What can we learn from our colleagues - thinking outside of the box.
Sponsored by Cirdan
Advanced Specialist Diploma (ASD)n in Histological Dissection
Advanced Specialist Diploma (ASD)n in Histological Dissection
Cellular Pathology
Learning outcomes
Following the presentation delegates will learn:
- Ideas on how to overcome barriers in training.
- Guidelines on producing a professional portfolio – what to include in the portfolio, what to audit, selecting case studies.
- Preparing for the exam and viva.
Abstract
In this session I will provide an overview of the changes that are being introduced to the Advanced Specialist Diploma (ASD) in Histological Dissection qualification.
Currently, after achieving the Diploma of Expert Practice in Histological Dissection candidates can undertake the ASD in Histological Dissection in one of three pathways (Breast, Lower Gastrointestinal and Urology). These are separate qualifications which can only be undertaken one at a time. I will explain how it is planned the ASD in Histological Dissection will be re-structured so that it is similar to the DEP and will allow candidates to undertake more than pathway at a time.
I will explain the reasons for these changes, the additional specialisms (pathways) that will be available and the changes that will be made to the portfolio and exam requirements as a result of the restructuring of the ASD.
Sponsored by Cirdan
Speakers
Chris Ward
The histopathology of COVID-19
The histopathology of COVID-19
Cellular Pathology
Learning outcomes
Delegates attending this presentation will:
- Have an appreciation of the rapid pace of elucidation of the pathology of COVID-19 by autopsy pathologists worldwide during the pandemic.
- Learn about the gross and microscopic morbid anatomical findings in COVID-19 as elucidated in published autopsy literature.
- Some coverage of potential pathophysiological mechanisms involved.
Abstract
The COVID-19 pandemic has brought to the forefront of the public eye science, medicine, pathology and hence biomedical science. The role virology has played in the international response is well recognised, but less so that of histopathology. Up to April 2020, there was a dearth of information on disease evolution at the organ and cellular level, but histopathologists worldwide soon responded to the clinical demand for autopsies in order to learn about the pathogenesis of this disease, which would ultimately help guide patient management and prevention strategies.
The aims of this talk are to provide an overview of the main systemic pathology observed in fatal adult COVID-19 disease, discussing the gross and microscopic findings observed in locally performed autopsies within our unit (Guy’s & St Thomas’ NHS Foundation Trust) and as reported in the published literature. This will include some discussion of putative pathophysiological mechanisms, and of ancillary viral detection methods including RT-PCR, immunohistochemistry, in-situ hybridisation and electron microscopy, and challenges in their interpretation. An overview of an autopsy strategy for an emerging disease, including post-mortem safety measures, will also be presented.
Sponsored by Cirdan
Advantages & disadvantages of using CT for post-mortem examination
The benefits of including pathology in multidisciplinary training days for forensic paediatric post–mortems
The benefits of including pathology in multidisciplinary training days for forensic paediatric post–mortems
Cellular Pathology
Learning outcomes
Delegates will:
- Understand the role of the anatomical pathology technologist (APT).
- Be aware of the difference APT's can make in pathology.
- Understand the value of training and education in a multi-disciplinary setting.
Sponsored by Cirdan
UK NEQAS Tissue EQA Scheme
UK NEQAS Tissue EQA Scheme
Cellular Pathology
Learning outcomes
Delegates will:
- Understands the background to new Tissue EQA Scheme
- Be able to appreciate the benefits of the new scheme
- Learn about the progress so far
Abstract
The original slide-based External Quality Assurance (EQA) scheme for routine histopathology was devised 30 years ago. From this, a comprehensive portfolio of testing programmes covering a broad range of histopathology services has been developed. The original ‘General’ scheme assessed archival haematoxylin and eosin (H&E) stained slides, and special staining of slides distributed by the scheme. This assessment model stood the test of time and provided participants with an independent quality assurance and proficiency testing service for laboratory core work.
However, following a change in accreditation, the demonstration of compliance with ISO 15189:2012 standards through data analysis, validation and participation in inter-laboratory EQA schemes became a more pressing requirement. The change prompted UK NEQAS Cellular Pathology Technique, as it is known today, to review the ‘General’ scheme design.
The concept was to increase quality initiatives by the assessment of not only the H&E stained slide, but also the quality of its associated paraffin wax processed tissue block. The proposal was expanded further to examine quality output from individual tissue processors, thus providing a more representative assessment of processing, by introducing asset specific participation.
Following a successful pilot, the review led to the implementation, in May 2021, of the new ‘Tissue Diagnostics’ scheme and for assessment of special stains, the separate ‘Specialist’ scheme. For the Tissue Diagnostics scheme, mandatory online data entry at registration has allowed us to gather and present information about methodology, equipment and reagents in use. Data analysis is proving to be very useful to participants in a number of ways.
An example is a new option for participants to re-evaluate the way Tissue Diagnostics scheme results are reviewed, enabling the monitoring of variations between processing machines. In this presentation, we will look at the impact of the Tissue Diagnostics scheme, results so far and trends observed through assessment.
Sponsored by Cirdan
Speakers
Jane Woods
The evolution of EQA through Pathology Modernisation
The evolution of EQA through Pathology Modernisation
Cellular Pathology
Learning outcomes
Following the presentation delegates will learn:
- The history, impact and development of Cellular Pathology EQA
- Their diagnostic implications and educational implications
- Current format for compliance with ISO 15189 guidance.
Sponsored by Cirdan
Clinical Chemistry
Monitoring asparaginase activity to inform treatment of acute lymphoblastic leukaemia
Monitoring asparaginase activity to inform treatment of acute lymphoblastic leukaemia
Clinical Chemistry
Learning outcomes
Method development and assay validation procedures.
Abstract
Asparaginase is an important component of therapy for acute lymphoblastic leukaemia (ALL) due to the anti-neoplastic effect in patients. Allergic reaction to the foreign protein may lead to inactivation. Enzyme neutralization in the absence of apparent symptoms, termed silent inactivation, represents a significant threat to patient well-being. There is need to monitor activity in patients to optimise dosage and prevent relapse. Our aims were to establish a monitoring assay and assess utility by measuring serial activity in patient serum.
In the Department of Chemical Pathology, Great Ormond Street Hospital (GOSH), London, UK, a colorimetric assay based on a previously described method was established and verified. Twenty children newly diagnosed with ALL and commencing the ALL2011 UK treatment protocols were recruited by the Department of Haematology and Oncology, GOSH. Serum samples were collected at various time points after enzyme administration and assayed.
Asparaginase activity in 13 patients remained above therapeutic threshold (>100U/L) up to 14 days after treatments, without apparent allergic reaction. Two patients exhibited severe immune reaction: serum activity was consistent with clinical picture in one patient. Three patients displayed undetectable activity 11 days after last treatment delivery, possibly suggesting silent inactivation. One patient showed activity considerably below therapeutic threshold 12 days after treatment and may benefit from increased dose. Looking forward, the patient study demonstrated clinical utility of the assay in children with ALL.
Findings suggested 15% of patients may exhibit silent inactivation of the enzyme, a potentially high incidence that warrants a larger scale trial to further investigate and correlate activity with clinical outcomes. We are now monitoring asparaginase treatment in all UK patients recruited to the European-wide ALLTogether trial. The primary objective is to collect data on leukaemia-specific outcomes for ALL patients. Asparaginase monitoring will optimise standard of care by informing use of asparaginase.
Sponsored by Ortho Clinical Diagnostics
How will the challenges of the pandemic impact how we offer future Clinical Biochemistry services?
How will the challenges of the pandemic impact how we offer future Clinical Biochemistry services?
Clinical Chemistry
Learning outcomes
The COVID pandemic has caused massive global challenges logistically, emotionally and even personally to most of the world’s population. This added to the complexity of Brexit has resulted in challenges in keeping a biochemistry service running. Lean and just in time processes came under significant strain due to global shortages and blocks in the logistical chain, be it through lack of consumables, customs blocks and people not being available to provide services.
The pandemic also forced any businesses into a new way of working, healthcare included. This impacted how people interacted with accessing healthcare, staff availability and staff skill sets as departments managed new infection control requirements whilst maintaining the service. This now is an opportunity to build on these lessons and use these to remodel the service to align with the changes in the way healthcare is delivered.
Sponsored by Ortho Clinical Diagnostics
Speakers
Dr David Ricketts DBMS CSci FIBMS
Harveys Gang: From the lab to the ward
Harveys Gang: From the lab to the ward
Clinical Chemistry
Learning outcomes
Delegates attending this presentation will be able to:
- Describe Harvey’s Gang project and its applications.
- Understand how laboratory chemistry can be incorporated into Harvey’s Gang project.
- Understand how laboratory methods demonstrated are used in the care of Harvey’s Gang patients.
- Explain examples of where laboratory chemistry has been demonstrated to Harvey’s Gang.
Abstract
In this presentation, Sophie will demonstrate how the charity has helped translate the work performed in the labs to the those most vulnerable, to improve their experience in the hospital, and get both patients, carers and parents involved with each step of the care pathway.
Sponsored by Ortho Clinical Diagnostics
Speakers
Sophie Ward
Spectrum of conditions associated with paraproteins - From laboratory to the clinic
Spectrum of conditions associated with paraproteins - From laboratory to the clinic
Clinical Chemistry
Learning outcomes
Delegates attending this presentation will be able to :
- Identify the clinical features of plasma cell disorders, including myeloma, plasmacytoma, plasma cell leukaemia, and lymphoplasmacytic disorders such as Waldenstrom’s macroglobulinaemia.
- Explain how laboratory investigations, such as protein electrophoresis and serum free light chains, are translated into the clinical picture and patient management.
- Learn how plasma cell disorders are monitored.
Abstract
A paraprotein is an abnormal protein produced by plasma cells in the bone marrow. These Plasma cell dyscrasias (PCD) are a heterogeneous group of conditions the most common of which is Monoclonal Gammopathy of Undetermined Significance (MGUS).
This premalignant PCD consistently precedes multiple myeloma (MM) and lymphomas depending on the paraprotein subtype with a 1% risk of progression per year. Paraprotein as a biomarker of disease has withstood the test of time. The quantification and identification is of crucial importance in the diagnosis, monitoring and treatment of patients with PCD.
Sponsored by Ortho Clinical Diagnostics
Speakers
Dr Aaron Niblock MB Bch BAO MRCP FRCPath MSC
Cerebrospinal fluid (CSF) biomarkers in the investigation of patients with dementia
Cerebrospinal fluid (CSF) biomarkers in the investigation of patients with dementia
Clinical Chemistry
Learning outcomes
Delegates attending this presentation will:
Understand how CSF biomarkers may help in the differential diagnosis of patients with dementia
Abstract
Dementia is a major public health concern that will increase in the next decade due to the ageing population. This means that there is increasing need for the development of sensitive and disease-specific diagnostic tests. These tests will enable earlier and more accurate diagnosis to be made and ensure that therapeutic interventions and active support for both the patient and their families are given as soon as possible. There has been extensive research into the use of cerebrospinal fluid (CSF) biomarkers for the diagnosis of Alzheimer's Disease (AD).
Reduced concentrations of β-amyloid in conjunction with elevated tau protein and/or hyper-phosphorylated tau protein have been proposed biomarkers of AD. The recent development of Real-time Quaking induced Conversion (RT-QuIC), a highy sensitive technique for detecting misfolded proteins associated with Creutzfeldt-Jakob disease and Lewy body dementia, has enabled the accurate diagnosis of these rre forms of dementia. The impact of recent analytical advances on the future of dementia diagnosis will be discussed.
Sponsored by Ortho Clinical Diagnostics
Demand optimisation in a post-COVID world
Tumour markers for today and tomorrow
Tumour markers for today and tomorrow
Clinical Chemistry
Learning outcomes
Delegates attending this presentation will be able to :
- Summarize the current state and clinical applications of tumour markers.
- Understand the limitation and benefits of PSA in screening for prostate cancer.
- Discuss the merits and problems in using tumour markers (e.g., CEA, CA 125) in post-operative surveillance and monitoring therapy.
- Gain an insight as to the future use of tumour markers, including the potential transformative use of circulating tumour DNA (ctDNA).
Sponsored by Ortho Clinical Diagnostics
Speakers
Professor Joe Duffy
Essential contribution of laboratory diagnostics in COVID-19
Essential contribution of laboratory diagnostics in COVID-19
Clinical Chemistry
Learning outcomes
Delegates attending this presentation will have an understanding of:
- How COVID-19 can be diagnosed with molecular and antigen testing
- The role of serology in monitoring immune response after COVID-19 and vaccination
- The role of laboratory tests for predicting unfavourable outcomes in patients with SARS-CoV-2 infection
Abstract
The global coronavirus disease 2019 (COVID-19) has presented major challenges for clinical laboratories, from initial diagnosis to patient monitoring and treatment. Initial response to this pandemic involved the development, production, and distribution of diagnostic molecular assays at an unprecedented rate, leading to minimal validation requirements and concerns regarding their diagnostic accuracy in clinical settings. In addition to molecular testing, serological assays to detect antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are now becoming available from numerous diagnostic manufacturers.
In both cases, the lack of peer-reviewed data and regulatory oversight, combined with general misconceptions regarding their appropriate use, have highlighted the importance of laboratory professionals in robustly validating and evaluating these assays for appropriate clinical use. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on COVID-19 has been established to synthesize up-to-date information on the epidemiology, pathogenesis, and laboratory diagnosis and monitoring of COVID-19, as well as to develop practical recommendations on the use of molecular, serological, and biochemical tests in disease diagnosis and management.
This lecture summarizes the latest evidence and status of molecular, serological, and biochemical testing in COVID-19 and highlights some key considerations for clinical laboratories operating to support the global fight against this ongoing pandemic. Confidently this consolidated information provides a useful resource to laboratories and a reminder of the laboratory's critical role as the world battles this unprecedented crisis.
Sponsored by Ortho Clinical Diagnostics
Speakers
Professor Giuseppe Lippi
Biomarkers in the diagnosis of sepsis
Urgent Biochemistry – impact of the 1 hour TAT in the ED, does it benefit patients?
Urgent Biochemistry – impact of the 1 hour TAT in the ED, does it benefit patients?
Clinical Chemistry
Learning outcomes
This presentation will discuss:
- Which tests are of importance in the context of a 1-hour TAT and why?
- How does the 1-hour TAT matter to the patient and patient outcomes?
- Operational and workflow impact in a busy emergency department.
- Point of care versus laboratory based tests - advantages & disadvantages.
Abstract
The target turnaround time for samples collected in the Emergency Department is less than one hour. This presentation will address the clinical importance of achieving a one-hour turnaround time, identifying the tests where a short turnaround time is of greatest importance for patient care.
The talk will cover the link between turnaround time and clinical outcomes and will discuss practical implications for workflow in the Emergency Department. Finally, the advantages and disadvantages of using point of care testing to achieve a shorter turnaround time will be discussed.
Sponsored by Ortho Clinical Diagnostics
Speakers
Professor Richard Body
COVID-19: Cross skilling of healthcare workers
COVID-19: Cross skilling of healthcare workers
Clinical Chemistry
Learning outcomes
Delegates attending this presentation will:
- Learn about the core skills and how to create tools to aid in rapid re-skilling.
- Understand how multi-professional educational resources are developed.
Sponsored by Ortho Clinical Diagnostics
Clinical Scientist Experiential Route and Process and Q&A with the Clinical Chemistry Higher Specialist Diploma (HSD) Examiners
Clinical Scientist Experiential Route and Process and Q&A with the Clinical Chemistry Higher Specialist Diploma (HSD) Examiners
Clinical Chemistry
Learning outcomes
Delegates attending this presentation will:
- Learn about the process of applying for HCPC registration as a Clinical Scientist via the IBMS Experiential Route.
- Be able to meet and discuss areas of HSD examination with an examiner and HSD candidate including learning about the benefits of undertaking this qualification.
Sponsored by Ortho Clinical Diagnostics
Speakers
Sheri Scott
Dr Nigel Brown
Jennie Kettlewell
Jamie West
Future of Clinical Biochemistry – health informatics and bioinformatics
Future of Clinical Biochemistry – health informatics and bioinformatics
Clinical Chemistry
Learning outcomes
Delegates will:
- Understand what big data & machine learning has got to do with the laboratory
- Learn how laboratory data can add value to diagnosis and prognosis
- Be given real world examples of how health informatics & bioinformatics are being used
- Learn about future developments.
Abstract
&Harnessing the information revolution and big data is one of the key pillars of transformative innovation in healthcare, and is crucial to deliver the long-term NHS plan (https://www.longtermplan.nhs.uk) that places emphasis on early detection and prevention of disease.
Clinical Laboratory Diagnostics Services are expected to be at the forefront of this digital revolution. Over the past decade, advances in the analytical performance of machine learning (ML) has improved significantly clinical and laboratory data utilisation. An area where ML is expected to play a leading role is to refine understanding of existing care processes to ensure their configuration is appropriate and based on robust evidence. This is particularly important since there is challenging demand to deliver healthcare to an ageing population with a growing number of complex long-term conditions.
The lecture will discuss how laboratory data can add value to diagnosis and prognosis and present exemplar real world examples of how health informatics & bioinformatics are being used.
Sponsored by Ortho Clinical Diagnostics
A case of pseudohyperkalaemia and pseudo-hypercalcaemia in a patient with acute myeloid leukaemia with thrombocytosis
A case of pseudohyperkalaemia and pseudo-hypercalcaemia in a patient with acute myeloid leukaemia with thrombocytosis
Clinical Chemistry
Learning outcomes
Through the discussion of a case study delegates will learn that:
- Awareness of pseudo elevations of biochemical analytes not just commonly seen ones such as Potassium
- Importance of ensuring biochemical parameters are assessed in conjunction with FBC parameters
- Lithium heparin or anticoagulated samples rather than serum can be helpful in these cases.
Abstract
An unusual biochemical presentation in a patient with acute myeloid leukaemia. The patient was a generally unwell GP patient with the highest platelet count we have seen to date. The patient had such extreme platelet counts it caused significant changes to the routine biochemistry monitoring while the patient was at our hospital.
Pseudo hyperkalaemia is a regular problem and widely reported phenomenon in the biochemistry laboratory particularly with regards to myelproliferative disorders. This particular case had the much more uncommon issue of causing possible pseudo hypercalcaemia also, as well as affecting other parameters such as phosphate. In order to obtain useable accurate potassium levels for this patient we recommended the use of lithium heparin plasma samples, however we would routinely only receive serum samples; this gave an alternating serum, plasma pattern and a quite dramatic yoyo situation for the biochemical parameters despite the patient being stable.
During the clotting of the serum sample in the tube the cellular contents of the vast quantity of platelets are released into the serum prior to centrifugation. The anticoagulant in the lithium heparin sample tube has protected and maintained the platelet integrity until centrifugation has effectively removed them from the plasma and prevented the contents from being shed causing the pseudo artifacts.
We lost track of this patient after they were transferred from our district general hospital to a specialist centre more suitable for their needs. I am sure the pathology service there had very similar issues…
Sponsored by Ortho Clinical Diagnostics
A case of myeloma diagnosed from a random urine protein
A case of myeloma diagnosed from a random urine protein
Clinical Chemistry
Learning outcomes
Through the discussion of a case study delegates will:
- Be able to describe the types of proteinuria (glomerular, tubular, overload and postrenal).
- Understand the analytical steps taken following discovery of an elevated random urine protein result.
- Be able to link the clinical presentation and test results to myeloma diagnosis.
Abstract
In this case study submitted as a piece of coursework towards the IBMS Higher Specialist Diploma in Clinical Chemistry we will discuss the case of an 83-year-old male who presented with an elevated random urine protein. Microalbumin levels contributed to less than 5% of the total urine protein and therefore further investigations were requested.
Repeat sample collection confirmed the initial results and urine electrophoresis revealed the presence of an abnormal band which was characterised as free lambda light chains by immunofixation. Clinical symptoms which indicated myeloma included bone pain, anaemia, and renal dysfunction.
This case study will explore the causes of proteinuria, laboratory diagnosis, and clinical presentation of myeloma.
Sponsored by Ortho Clinical Diagnostics
Speakers
Charlotte Atkin
A biochemistry Biomedical Scientist – roles and career development beyond the laboratory
A biochemistry Biomedical Scientist – roles and career development beyond the laboratory
Clinical Chemistry
Learning outcomes
Through attending this presentation delegates will:
- Gain knowledge in the development opportunities post-registration.
- Gain an awareness of skill development beyond the laboratory environment.
- Gain an insight into professional registration and where it can lead you.
- Learn how to access the different development opportunities.
Abstract
Continual professional development (CPD) is a professional mandatory requirement for a practicing Biomedical Scientist where the need to remain current and practice safely with continued quality are fundamental to patient safety. This presentation aims to provide a guide for anyone in a related biomedical science field be it biomedical or clinical scientist, technician, support grade or engineer. highlighting what CPD can do for them. This presentation looks at the roles available to the clinical and nonclinical laboratory professional, the different opportunities available for CPD and the transferable skills gained through these roles, which can open doors for career development.
From an awareness of skill development beyond the lab environment to an insight into different types of professional registration, this session will provide answers on how to access the different development opportunities.
Sponsored by Ortho Clinical Diagnostics
Speakers
Sheri Scott
Cannabis and cannabidiol with a dash of spice. What is all the fuss about?
Biochemical screening for phaeochromocytoma and paraganglioma (PPGL)
Biochemical screening for phaeochromocytoma and paraganglioma (PPGL)
Clinical Chemistry
Learning outcomes
Delegates attending this presentation will:
- Understand the physiology of hormone excess in PPGL and how this can be used in the laboratory to screen patients.
Abstract
Phaeochromocytomas and paragangliomas (PPGL) are rare catecholamine-producing tumours, which can have a wide range of clinical presentations depending on the catecholamine being overproduced. Autopsy examinations suggest that many PPGL remain undiagnosed in life; therefore, sensitive screening methods are essential to increase detection of PPGL both in specialist centres for those with genetic predisposition to PPGL and within the community at large. Significant advances in the search for an ideal biomarker have been made; however, this has resulted in confusing terminology and variable practice.
The aim of this presentation is to provide insight into the methodologies currently recommended by the best practice guidelines, their limitations and possible progress being made in this area..
Sponsored by Ortho Clinical Diagnostics
Reproductive Biochemistry – Biochemistry in pregnancy
Reproductive Biochemistry – Biochemistry in pregnancy
Clinical Chemistry
Learning outcomes
Delegates attending this presentation will be able to :
- Understand the development of maternal serum screening.
- Explain how different factors influence the chance result.
- Describe the benefits and pitfalls of the screening programme.
Sponsored by Ortho Clinical Diagnostics
Pre-eclampsia markers: Current status in clinical practice
Pre-eclampsia markers: Current status in clinical practice
Clinical Chemistry
Learning outcomes
Delegates attending this presentation will:
- Understand the physiological changes associated with angiogenic markers in pregnancy and how these can be disturbed in pre-eclampsia
- Understand the diagnostic benefits of providing these tests in clinical practice including the high negative predictive value
- Understand the available methods for these markers used in practice
- Be able to access NICE guidance (currently being updated) on their use.
Sponsored by Ortho Clinical Diagnostics
Speakers
Professor Tim James
COVID-19: Clinical Chemistry lessons learned
COVID-19: Clinical Chemistry lessons learned
Clinical Chemistry
Learning outcomes
Delegates attending this presentation will be able to:
- Understand the impact of a global pandemic on the provision of local Blood Science laboratory services
- Explore the ways in which laboratory services and their staff can adapted to rapidly changing clinical requirements.
- Review how the laboratory is supporting a return to (the new) normal service, including the provision of serology testing.
- Assess the impact that the demands SARS-CoV2 has placed on laboratory staff and what ongoing support is required to ensure their future well-being.
Abstract
The SARS COV-2 pandemic has presented unprecedented demands on healthcare services across the world, none of us will ever forget the television reports showing the desperate conditions in which patients and staff found themselves. Laboratory services were crucial to the healthcare response, however, our role was most often behind the scenes supporting clinical services.
In this session I will review the impact of a global pandemic on the provision of local Blood Science laboratory services, we will explore the ways in which laboratory services and their staff adapted to rapidly changing clinical requirements and appraise our achievements. We will review the laboratory response to the pandemic and consider how our role will change as we face new challenges when we move towards a recovery phase. Finally, we will assess the impact that the demands SARS-CoV2 has placed on laboratory staff and what ongoing support is required to ensure their future well-being.
Sponsored by Ortho Clinical Diagnostics
COVID-19 antibody testing: A cross-discipline approach
COVID-19 antibody testing: A cross-discipline approach
Clinical Chemistry
Learning outcomes
Delegates attending this presentation will be able to :
- Understand the processes behind COVID antibody testing.
- Evaluate of the different techniques involved with COVID antibody testing.
- Recognise the need for cross-discipline working during a pandemic.
Sponsored by Ortho Clinical Diagnostics
Speakers
James Murphy
Paula Griffiths
Pathology in a pandemic. Establishing pathology provision at the UK's first NHS Nightingale Hospital
Pathology in a pandemic. Establishing pathology provision at the UK's first NHS Nightingale Hospital
Clinical Chemistry
Learning outcomes
Delegates attending this presentation will understand:
- The clinical requirements of the service
- How Pathology Services at the Nightingale London were established
- Challenges of providing pathology services at the nightingale
- Lessons learnt.
Abstract
In order to provide extra critical care capacity at the start of the COVID-19 pandemic, plans were made by the government and NHS England to open new field hospitals across the country, the first being in London where the number of COVID-19 cases was highest. Within two weeks, the Excel centre was converted from an exhibition space to a field hospital. This required establishing new clinical teams and processes, installing IT and communication systems, building wards, sourcing equipment and supplies and providing pathology, pharmacy and imaging services among others.
As there were no existing pathology services on site, decisions had to be made as to what services were required on- and off-site to meet the clinical needs of the hospital, and how these could be provided within such a short timeframe. A project team consisting of NHS staff from across organisations, management consultants and military personnel was assembled and tasked with establishing these core services.
In this talk we will give an overview of pathology services at NHS Nightingale London and how they were established. We will also discuss the challenges faced along the way, how these were tackled and the lessons learnt.
Sponsored by Ortho Clinical Diagnostics
Speakers
Jenny Lake
Corrina Sampson
UK NEQAS Clinical Chemistry: More than a tick-box exercise
UK NEQAS Clinical Chemistry: More than a tick-box exercise
Clinical Chemistry
Learning outcomes
Through an interactive session delegates will:
- Understand the role of EQA within a Quality Management System EQA is not simply a secondary IQC or calibration tool
- Be able to get the most out of your UK NEQAS Clinical Chemistry EQA to support troubleshooting and ongoing assay verification
- Be aware of recent innovations within UK NEQAS Clinical Chemistry.
Abstract
EQA (External Quality Assessment) is sometimes seen as a 'chore' or 'just a UKAS requirement'. EQA is not just about detecting poor performance. In the majority of cases EQA should be reassuring you and your laboratory that you are providing an overall good quality of service. This lecture will show you that EQA is integral within your Quality Management System (QMS) and is beneficial not only for the routine and ongoing monitoring of your assay performance, but also for improved understanding of assays which may assist interpretation of 'odd results' or further Quality Improvement within your laboratory. Education is core to the services that we provide. This interactive session will explore some case examples and provide you with the tools to troubleshoot and get the most out of your EQA not only from an analytical perspective but also from personnel resource management.
It is the responsibility of the wider laboratory community to continuously assess whether the assays they are using are fit for purpose and whether the limits used in guidelines are valid and achievable to ensure we can all provide the best service possible for patients. EQA data contains information about the current state of the art performance of assays and is often an under used resource. This session will show you some of the questions you should be asking and where to look for information in EQA reports.
EQA services, like clinical laboratories, are continually improving. The final part will discuss recent innovations within UK NEQAS Clinical Chemistry from the Birmingham Quality perspective, including new Schemes, education and changes to reports and the website.
Sponsored by Ortho Clinical Diagnostics
The screening and quantification of gabapentin and pregabalin in post-mortem samplers using high performance liquid chromatographyhigh resolution mass spectrometry (HPLCHRMS)
The screening and quantification of gabapentin and pregabalin in post-mortem samplers using high performance liquid chromatographyhigh resolution mass spectrometry (HPLCHRMS)
Clinical Chemistry
Learning outcomes
Delegates will:
- Gain knowledge of Gabapentin and Pregabalin and how they are used in the treatment of epilepsy and neuropathic pain.
- Understand the use and misuse of these drugs and the role of the biochemistry department in their monitoring.
- Gain insight and knowledge of the screening methods currently used and the new methods being developed.
Abstract
The use of gabapentin and pregabalin has considerably increased in the UK since their introduction. These drugs have not only gained popularity in the UK, but across Europe and the USA, with studies showing increased use for illicit purposes. As a result, it has been decided that Sheffield Teaching Hospitals needs a robust method for the screening and quantitation of gabapentin and pregabalin in post-mortem blood.
Currently, Sheffield Teaching Hospitals employs a qualitative GC-MS screening of post-mortem samples after a ‘Basic’ extraction procedure. However, due to the lack of sensitivity of the GCMS assay as well as its inability to quantitate drug concentrations, a fully validated assay was developed for the screening and quantification of gabapentin and pregabalin in post-mortem (PM) blood. A simple protein precipitation extraction, using the deuterated analogues of the gabapentinoids as internal standards, was performed prior to analysis by HPLC-HRMS.
Analysis showed a linear calibration curve for both gabapentin and pregabalin with R2 values above 0.999 for each run. Intra-assay imprecision was assessed giving %CVs of <10%. Inter-assay imprecision was determined using one-way ANOVA. There was no clinically significant variation between QC analysed over 5 days. The average recovery for gabapentin and pregabalin was evaluated using EQA and gave a recovery value 97%.
The limits of detection and quantification were determined for both gabapentininoids. No carry over was observed in post-mortem analysis. Ion suppression tests showed there is no ion suppression or enhancement. Although a screening and quantitative method was developed, PM sample analysis and comparison are yet to be performed.
Sponsored by Ortho Clinical Diagnostics
Dinitrophenol – more than an explosive
Dinitrophenol – more than an explosive
Clinical Chemistry
Learning outcomes
Delegates will:
- Gain knowledge on the ilicit use of dinitrophenol
- Learn about the mode of action
- Gain insight of its involvement in fatalities.
Abstract
Dinitrophenol has a chequered history and is used in the manufacture of explosives, dyes and can be used as a wood preservative, herbicide and insecticide. It was used to treat obesity, but was found to cause cataract formation as well as fever, shortness of breath and sweating. Vast quantities were used in the first world war in the manufacture of munitions with at least one case of liver cancer being attributed to occupational exposure to the drug. It is now being marketed (illicitly) as a weight loss aid for body builders.
This talk will briefly discuss the history of its use as a drug and weight loss aid, review its mechanism of action and outline the clinical features associated with its use.
Sponsored by Ortho Clinical Diagnostics
Laboratory based drug adherence testing
Laboratory based drug adherence testing
Clinical Chemistry
Learning outcomes
This presentation will cover:
- Anti-hypertensive drug screening
- Hypertension
- Patient compliance with treatment
Abstract
Nonadherence to antihypertensive medication is common, especially in those with apparent treatment-resistant hypertension and its routine detection is supported by clinical guidelines. Chemical adherence testing is a reliable and valid method to detect adherence, yet methods are unstandardised and are not ubiquitous.
In this talk Dr Lawson will outline some of the techniques used for laboratory-based drug adherence testing in hypertension and in other conditions. He will also highlight issues related to ethics, sample collection, transport, stability, sample type, pharmacokinetics, instrumentation, and gaps in knowledge.
Sponsored by Ortho Clinical Diagnostics
Speakers
Dr Alexander Lawson
How low are some people prepared to go? Hypoglycaemia and murder
Cytopathology
Tissue recognition programme - introduction
Upper and lower GI including endocrine
Gynaecological case studies
Skin case studies
Fluid, Respiratory, Urology case studies
Breast case studies
HPV Screening – Four Nations update
HPV Screening – Four Nations update
Cytopathology
Wales: Louise Dunk, Public Health Wales
Scotland: Gillian Collins, NHS Greater Glasgow & Clyde, Queen Elizabeth University Hospital
Northern Ireland: Jackie Jamieson, Northern Health and Social Care Trust
England: Dr Karin Denton, Severn Pathology North Bristol NHS Trust
Abstract
Wales
Cervical Screening Wales (CSW) rolled out HPV primary screening in September 2018, following an implementation pilot which ran for 18 months and involved over 20% of women invited for screening. The cervical screening laboratory structure was reorganised in Wales to accommodate this change, and reduced to one laboratory for HPV testing and LBC processing, cytology screening and checking and a clinical network of Pathologists and Consultant BMS staff across Wales.
The Coronavirus pandemic saw a pause in the issue of invitations for cervical screening for three months, although colposcopy appointments continued to be offered as normal by all health boards. Recovery from the pause is now complete and cervical screening invitations are being issued when due. Due to their continued support of the Public Health Wales Coronavirus pandemic response, the Informatics team has been unable to produce the programme's annual statistical reports for the past two years, nor any other reports except those required for the routine operation and governance of the programme. We are unable therefore to update on years two and three of the HPV rollout other than basic performance monitoring, and hence this update will also cover more general programme changes over the past two years.
On 1st January 2022 CSW extended the screening intervals to five years for those aged 25 - 49 who test negative for HPV, in line with UKNSC recommendations and Welsh Government approval. Unfortunately this change was met with an adverse response by the public, resulting in backlash on social media and two petitions to get the change reversed. The mainstream media and leading charitable organisations were supportive of the change, which was upheld in a subsequent Senedd debate.
CSW is now in the final stages of development for the replacement of the NHAIS/Exeter system - CSIMS. This has been delayed due to the pandemic and resulting pressures on the screening programme and PHW Informatics team. Go-live is expected in spring 2022. Development of a replacement system for the national colposcopy database, Canisc, is also underway, with an expected go-live in October 2022.
Planning for an implementation study of self taken samples in Wales is continuing, with discussions taking place with NHSE about collaboration in their national pilot.
Speakers
Dr Karin Denton
Louise Dunk
Gillian Collins
Jackie Jamieson
Liquid Based Cytology - Rapid molecular testing using the Biocartis Idylla Platform
Liquid Based Cytology - Rapid molecular testing using the Biocartis Idylla Platform
Cytopathology
Learning outcomes
Delegates attending this presentation will understand:
- Utilisation of liquid-based cytology samples for molecular testing
- The role of ROSE in molecular testing
- Importance of rapid turnaround times in cancer pathways.
Abstract
Technical medical advancements have moved to minimally invasive procedures for patients resulting in smaller diagnostic samples. In contrast pharmaceutical developments have lead to the requirement for more information to be extracted from these smaller samples. Cytology services can effectively and rapidly provide essential information to support diagnostic requirements by identifying targeted and highly specialised prognostic and therapeutic biomarkers leading to personalised treatments for patients.
This presentation introduces the KEBI-CYTO trial which focused on validating optimally preserved residual liquid based cytology samples and blood plasma samples for the detection of driver mutaions in non small cell lung carcinoma and pancreatic adenocarcinoma.
Speakers
Leonie Wheeldon
Enduring impact of HPV vaccination on infection and disease: 10 years and counting
Enduring impact of HPV vaccination on infection and disease: 10 years and counting
Cytopathology
Abstract
Prophylactic HPV immunisation has been live in UK for over 10 years and we are seeing the consequences on infection and disease increasingly. The talk will cover uptake and impact of the vaccine when delivered as a single-gender and gender neutral strategy and also consider the implications of vaccinating other groups, outside the routine programme.
Considerations for future primary and secondary disease prevention in an era of vaccination will be discussed as well as new vaccine technologies and approaches to administration
Speakers
Dr Kate Cuschieri FRCPath
Next-generation sequencing and applications for HPV testing
Next-generation sequencing and applications for HPV testing
Cytopathology
Abstract
Molecular tests for the detection of human papillomavirus (HPV) infection in humans have evolved dramatically over the last decades. Initial low-throughput hybridization/blotting techniques have been replaced by rapid high-throughput target-amplification assays. These tests can detect individual HPV genotypes and have become the mainstay of HPV-based screening and clinical testing.
The next “age” of HPV testing should involve going beyond simply detecting the presence or absence of HPV but rather, provide more detailed insight into the likely course and clinical consequences of HPV infection.
Next generation sequencing (NGS) can be used as a highly sensitive method for HPV detection due to its ability to detect types at low copy numbers (even within multiple infections), novel types, and/or known types that are distantly related to primers/probes which may escape detection using standard molecular approaches.
Speakers
Daniel Guerendiain
Self–sampling for cervical screening: The YouScreen trial
Self–sampling for cervical screening: The YouScreen trial
Cytopathology
Abstract
HPV self-sampling is poised to be a disruptor for cervical screening. Its appeal is obvious – women can collect a vaginal sample themselves at home using a swab or brush, foregoing the intimate (and often dreaded) speculum examination. This makes self-sampling less invasive and substantially more convenient than conventional screening, thereby increasing the acceptability and accessibility of cervical screening. It is hoped that self-sampling will help reverse the longstanding trend of falling coverage rates and will help address inequalities by reaching underserved populations. Furthermore, in the era of Covid-19 the introduction of self-sampling will help build much needed resilience into cervical screening programmes.
Seventeen countries have already introduced it into their national programmes or guidelines but it is yet to be introduced in the UK. Growing evidence on the accuracy of HPV testing on self-samples have prompted moves from several countries to offer self-sampling as a primary screening test.
The YouScreen trial is a pragmatic feasibility implementation clinical trial of HPV self sampling for non-attenders which integrated self sampling into the NHS the first time. YouScreen was conducted in parts of North Central and North East London in 2021. This session will provide an overview of self-sampling (including advantages and disadvantages), the YouScreen trial study design and its expected outputs/impact.
Speakers
Hasit Patel
Workshop on Cervical Cancer audit & MDT case presentations
Andrology: Is that allowed? Breaking the stereotypes of a Healthcare Scientist
Andrology: Is that allowed? Breaking the stereotypes of a Healthcare Scientist
Cytopathology
Abstract
Healthcare Scientists (HCS) make up a significant proportion of the NHS workforce and consist of four main arms: life sciences, physiological sciences, physical sciences & biomechanical engineering and bioinformatics. Andrology falls under ‘life sciences’ and is often viewed as a mainly laboratory-based role with minimal/no clinical input or patient management.
This talk will challenge the classical notion of a ‘laboratory scientist’ and demonstrate that with the right support we can use our knowledge and skills to undertake a more clinical role and manage/support patients. This expands the possibility of role development and ensures that the NHS have a more flexible and robust workforce to reflect the demands placed upon it.
Speakers
Stuart Long
Education and Training
Degree laboratory placement, the success of the symbiotic relationship
Degree laboratory placement, the success of the symbiotic relationship
Education and Training
Abstract
The presentation on degree laboratory placements, the success of the symbiotic relationship will cover the approach that has been developed over time to establishing and maintaining effective relationships with practitioners in local NHS laboratories.
A close relationship with local practitioners and laboratory managers is key to developing and delivering Biomedical Science degree programmes that are fit for purpose and contain relevant and current pathology content, in addition to supporting placement provision for our students. I have organised and chaired regular Employer Liaison Group meetings since 2005 as a key component of our ongoing programme development and enhancement. A close working relationship with local laboratories underpins the curriculum design and delivery of taught sessions that include current working practices and information. We regularly have colleagues from Pathology disciples delivering taught content in modules and producing case studies / data analysis tasks for students. Practitioners also help us to prepare our students for NHS placements by providing short visits to each laboratory in year 1, being on the interview panel to select students prior to their placement and facilitating peer mentoring from returning placement students about their experiences in the laboratory. We have been commended by sequential IBMS accreditation panels for our close relationship with employers.
Further, we provide regular Training for Trainers events at the university for practitioners who supervise placement students completing their IBMS registration training portfolio. Our Placement Tutor meets with all placement students and their trainers and is available for discussions and advice before, during and after the placement. We also provide mentor training for workplace supervisors / mentors of Healthcare Science Practitioner degree apprentices, alongside regular tri-partite meetings with the apprentice, trainer and work-based learning tutor from the university.
Sponsored by Sonic Heathcare UK
Speakers
Dr Sue Jones PFHEA, FIMBS, MRSB
Dr Claire Wright
Supporting learning using a virtual environment
Supporting learning using a virtual environment
Education and Training
Abstract
One of the impacts of the pandemic has been to accelerate the use of technology for learning, not only in compulsory and higher education but also in staff training and professional development.
In this presentation we’ll explore the different ways in which technology is being used to support education and skills development, and also look at how to make virtual learning accessible, flexible, effective and well supported.
Sponsored by Sonic Healthcare
Speakers
Andrew Pember
Recognising and supporting the role of the laboratory trainers
Recognising and supporting the role of the laboratory trainers
Education and Training
Abstract
Is training a “Cinderella role”?
This presentation will look at how to identify individuals suitable to become a trainer, what characteristics they need and what tools are required to undertake the trainer role successfully. Information obtained from a survey of training officers will be used to show their opinions of their roles and their suggestions for anyone considering the role.
It will explore the “Cinderella” status of training compared to quality and safety.
Sponsored by Sonic Healthcare UK
Speakers
Dr Mike Carter
Too busy to train?
Too busy to train?
Education and Training
Abstract
Are you responsible for laboratory training? Do you struggle to find time to fit training in around other duties and responsibilities?
This session will look at some hints and tips from experienced training officers as to how they have approached this in their own laboratories.
Sponsored by Sonic Healthcare UK
Speakers
Victoria Moyse
Spotting qualification fraud
Spotting qualification fraud
Education and Training
Abstract
Qualification fraud is a global problem, and the UK is a high-profile target for the fraudsters. Although most recruiters will ask to see the academic qualifications of their hires, only a minority check the data with the awarding body. This creates an opportunity gap which is filled by fake certificates, inflated grades and bogus universities and institutes. The consequences of not making the proper checks can be significant, and not just financially – major employers have suffered reputational damage when it becomes known that they have hired senior staff who used false credentials.
Qualification fraud takes ingenious forms, with the fraudsters often keeping step with the latest developments in security technology. But there are also straightforward ways to spot qualification fraud that can be folded into a best practice policy that protects both the recruiter and the honest applicant.
Sponsored by Sonic Healthcare
Speakers
Adam Crosbie
Qualification choices: HSD v MSc
Qualification choices: HSD v MSc
Education and Training
Abstract
Chris will provide an overview of the key IBMS Higher Specialist Diploma (HSD) qualification. He will outline the aims and learning outcomes of the HSD, explain who it is aimed and describe how the qualification is assessed by explain the requirements of the portfolio and the structure of the examinations.
Chris will also explore who might want to undertake an MSc and will explain the different individuals these qualifications are aimed at.
Sponsored by Sonic Healthcare UK
Speakers
Chris Ward
Opening HSST to biomedical scientists
Opening HSST to biomedical scientists
Education and Training
Abstract
The NHS is under constant pressure to meet the growing acute and chronic healthcare needs of the population and key to delivery of clinical services is a highly trained expert multi-professional workforce.
Within clinical laboratory diagnostic services reviews have highlighted shortages of medically qualified consultants. There is now a recognition that consultant scientists are well placed to help fill these gaps both in laboratory diagnostics or direct patient care or a mixture of both.
Outcomes from Modernising Scientific Careers has seen the development of the STP and HSST education and training programmes. However, until recently HCPC registration as a clinical scientist was an entry requirement to the HSST programme.
Following review, the HSST programme is now open to suitably qualified and experienced biomedical scientists, without the need to follow a clinical scientist equivalence route.
This now provides another career pathway for biomedical scientists who wish to develop and focus their knowledge and expertise in scientific and clinical patient care and an overview of entry criteria, application process, training programme and employer support will be discussed.
Sponsored by Sonic Healthcare
Speakers
Dr Jane Needham
New HCPC Standards of Proficiency: Changes, emphasis and impact
CPD – what can we learn from other professions?
CPD – what can we learn from other professions?
Education and Training
Abstract
Continuing Professional Development and Lifelong Learning are the lifeblood of professional practice. CPD can take many forms. 'Good' CPD brings benefits to our individual personal and professional life as well as to our service users. CPD requires the engagement of the individual, the support of the employer and the commitment of wider systems and policy makers.
This presentation will describe how 20 different professional bodies and trade unions came together to produce Principles for Continuing Professional Development and Lifelong Learning in Health and Social Care. It will also offer some tips on how to enjoy and get the most from your CPD.
Sponsored by Sonic Healthcare
Speakers
Gary Strong
Band 6 – finding, keeping, developing
Band 6 – finding, keeping, developing
Education and Training
Abstract
The profession as a whole has seen difficulties in recruiting Band 6 Biomedical Scientists - why?
How can we retain our current Band 6's and recruit others to vacancies that we have? There is no magical formula to address this, but the talk will focus on areas that can be targeted to make a department more attractive for staff to work in.
Sponsored by Sonic Healthcare
Challenges of delivering training with a limited scope service
Embedding leadership – training people to lead?
Embedding leadership – training people to lead?
Education and Training
Abstract
- A brief overview of leaders and leadership
- The traits of leaders and where to develop
- Knowledge required - focusing on yourself, your team and your environment
- Styles of leaders - what is the best fit.
Sponsored by Sonic Healthcare
Haematology
Morphology quiz
Morphology quiz
Haematology
Abstract
A selection of varied morphology cases, showing the fascinating world of the Biomedical Scientist reporting morphology and lessons for improving our decision making.
Cases where we gain clues from a small number of cells. Is it possible to make a morphological diagnosis from just a few key cells? No penalty, on-line quiz open to all with discussion and explanation of cases. A mixture of the common and the rare for all levels of experience. All you need is an interest in morphology. Multiple choice so anyone can do this.
Sponsored by Siemens Healthineers
Speakers
Dr John Burthem
Dr Michelle Brereton
The Integration of Morphology with Immunophenotyping and other modalities in haematological neoplasms
The Integration of Morphology with Immunophenotyping and other modalities in haematological neoplasms
Haematology
Learning outcomes
Delegates attending this presentation will be able to:
- Recognise a possible haematological emergency from the morphology and to explain what other diagnostic modalities should be employed to achieve a rapid diagnosis.
- Integrate morphology and immunophenotyping to reach a diagnosis
- Integrate morphology with information from cytogenetic, FISH and molecular analysis to reach a diagnosis.
Abstract
The Integration of Morphology with Immunophenotyping and other Modalities in the Diagnosis of Haematological Neoplasms.
Morphology, together with the full blood count, is key to the diagnosis of haematological neoplasms. Sometimes this alone permits a rapid and accurate diagnosis, which can be of considerable importance when the clinical condition is critical. On other occasions other modalities must also be employed. Immunophenotyping is of considerable importance in acute leukaemias and chronic lymphoid neoplasms. Cytogenetic and/or molecular genetic analysis is often also crucial. The integration of this information from these diverse sources will be exemplified by their application to acute myeloid leukaemias but lymphoid neoplasms will also be considered.
Sponsored by Siemens Healthineers
Speakers
Professor Barbara Bain
Immunodulatory drug resistance in myeloma
Immunodulatory drug resistance in myeloma
Haematology
Learning outcomes
Delegates attending this presentation will understand:
- The mechanisms of action of immunomodulatory drugs in myeloma including laboratory aspects of disease monitoring
- The mechanisms of resistance to immunomodulatory drugs in myeloma nosis.
Sponsored by Siemens Healthineers
Next-generation sequencing in myeloid neoplasms
Gene therapy: Curing the incurable!
Gene therapy: Curing the incurable!
Haematology
Abstract
Despite major advances in medical science, genetic conditions have remained incurable. Over the last decade however, gene therapy has emerged as potentially curative treatment for several hereditary conditions. Compared to other therapies, it is a fundamentally different approach that aims to treat the underlying cause of a disease at molecular level by providing a normally functioning gene to an individual who has inherited a pathogenic gene variant. Gene therapy has already been approved for spinal muscular atrophy and congenital blindness.
Results from clinical trials are extremely encouraging in haemophilia patients and show sustained coagulation factor levels for several years. While the landscape of treatment of genetic conditions is changing, these innovative approaches bring new clinical challenges and raise ethical issues.
In this lecture, the discussion will be on how these therapies are different from conventional approaches and the implications for pharmacovigilance and patient safety.
Sponsored by Siemens Healthineers
Anticoagulation in COVID-19: What does not kill
Anticoagulation in COVID-19: What does not kill
Haematology
Abstract
COVID-19 represents a unique challenge for the healthcare across the globe - a truly novel and unknown illness from which we have little evidence base to conclude best practice. It was recognised early on in the pandemic that patients were at risk of, and dying from, both macroscopic and microscopic thrombosis but those same patients were at significant risk of bleeding complications from anticoagulants which might resolve this.
Thromboprophylaxis given to prevent thrombotic disease has been used widely in the NHS for many years, but even those patients receiving this standard of care had a higher than expected rate of thrombosis.
This lecture discusses the mechanisms by which SARS-CoV-2 infection may cause thrombosis, the current trends around management and the data surrounding optimal anticoagulation in these patients.
Sponsored by Siemens Healthineers
The rise of misinformation and the role of science education
The rise of misinformation and the role of science education
Haematology
Learning outcomes
Delegates attending this presentation will learn:
- Whether COV-SARS2 induces lupus anticoagulant formation.
- How is this relevant clinically relating to survival.
- Will this produce long term side effects post infection.
Sponsored by Siemens Healthineers
Q&A. What we learnt from COVID-19
Q&A. What we learnt from COVID-19
Haematology
Learning outcomes
Through the discussion of questions submitted delegates attending this presentation will learn about:
- Changes in knowledge of the haemostatic system after the pandemic
- How the virus interferes with haemostasis
- What did we learn from the virus and its effects.
Delegates are asked to submit questions to [email protected] by Monday 31st January 2022.
Sponsored by
Speakers
Haemoglobinopathy conundrums - small details, big difference!
Haemoglobinopathy conundrums - small details, big difference!
Haematology
Learning outcomes
Through an interactive presentation based on case studies found in the Trust delegates will:
- Be made aware that since there are more than 1200 haemoglobin variants described and many other causing thalassaemia, the importance to acknowledge the complexity of HPLC interpretation.
- Understand the methods that are at their disposal to confirm the diagnosis.
- Be able to consider when it is necessary to request further testing in an environment of increasing financial pressures.
Abstract
Haemoglobinopathy screening and diagnosis is a very heterogeneous but fascinating specialist area to be working on. Specially with emerging new therapies, such as gene therapy, to treat or maybe even cure Sickle Cell Anaemia or Beta Thalassaemia Major. However, in an area where there are more than 1500 haemoglobin variants and thalassaemias described is easy to feel overwhelmed with the possibilities of diagnosis. Therefore, it’s very important to understand the basic principles of haemoglobinopathy diagnosis to be able to find the right and cost-effective solution for complicated cases.
High performance chromatography (HPLC) is one of the most used methods to separate haemoglobins in a reliable way. In this interactive presentation we will explore the diagnostic possibilities of several HPLC case studies, from the most commonly found in all laboratories to the more complex cases referred to us for investigation.
- How to ascertain if the patient has a haemoglobin variant with concomitant alpha or beta thalassaemia?
- How to ascertain if the variant is an alpha or beta chain variant or even both?
- Is the analyser, always right?
These are some of the questions we will answer together, and alongside a comprehensive explanation we will access the clinical significance, pitfalls and common errors in HPLC interpretation.
Sponsored by Siemens Healthineers
Speakers
Daniel Monteiro
Standardised testing for Paroxysmal Haemoglobinuria (PNH)
Standardised testing for Paroxysmal Haemoglobinuria (PNH)
Haematology
Learning outcomes
Delegates attending this presentation will learn that:
- PNH is a rare disease, consequently diagnosis can be delayed or completely missed.
- Laboratory testing plays a critical in role in the diagnosis of the disease, for which there is a highly effective treatment. Without therapy, morbidity and mortality can be significant.
- Previous studies have demonstrated the inconsistency of laboratory testing for PNH.
- We have developed international guidelines to assist with improving testing and therefore diagnosis of this rare disease.
Abstract
Paroxysmal Nocturnal Haemoglobinuria (PNH) is a rare disease. Clinical presentation is varied and diagnosis can be missed or delayed, potentially leading to patient mortality. Flow cytometry is the gold standard method and accurate testing is essential for diagnosis of PNH.
Studies have demonstrated significant issues with inter-laboratory accuracy and precision of this test, with false positive and negative results and high coefficient of variation. Improved standardisation has been shown to improve analytical performance of flow cytometry assays.
PNH guidelines have been developed and also demonstrate improved performance of PNH flow cytometry. The talk will include details of the international PNH guidelines and the steps taken to validate this assay in a multi-centre consensus group.
Sponsored by Siemens Healthineers
Gene therapy and bone marrow transplant treatment in beta thalassaemia patients
Gene therapy and bone marrow transplant treatment in beta thalassaemia patients
Haematology
Learning outcomes
Delegates will learn about
- The clinical and presentation of Beta Thalassaemia patients
- The diagnosis and categorisation of Beta Thalassaemia
- The current choices in gene therapy relevant to beta thalassaemia treatment
- How bone marrow transplant is used to introduce replacement genes in the patient.
Sponsored by Siemens Healthineers
Impact of COVID-19 on the haemostasis lab testing
Impact of COVID-19 on the haemostasis lab testing
Haematology
Abstract
Covid-19 has had a massive and hugely tangible impact to us all globally both on a professional and personal level. Barts Health had become the host Trust for NHS Nightingale, London when it opened on 2/4/2020. We very quickly had to implement a service for the whole of Blood Sciences including Point of Care Testing.
In this presentation I have tried to put into some persepctive the Royal London experience of the impact of Covid-19, both for the Haematology service and more specifically for the Haemostasis service.
Sponsored by Siemens Healthineers
Speakers
Minal Dave
Rebalancing the scales
British Society for Haematology Guidelines – platelet function testing
British Society for Haematology Guidelines – platelet function testing
Haematology
Learning outcomes
Delegates attending this presentation will gain knowledge on the recommendations from the BSH guideline writing group on various aspects including:
- Clinical evaluation and the utility of bleeding assessment tools
- Sample collection and preparation requirements
- Recommendations on phenotypic tests for investigation of platelet function
- Quality assurance measures available for platelet function testing
- Use of genetic or genomic testing in investigation of platelet disorders.
Abstract
This guideline replaces the previous British Committee for Standards in Haematology guideline published in 2011 on laboratory diagnosis of heritable disorders of platelet function. The remit has been expanded to include clinical diagnosis and heritable thrombocytopenia under the overarching term: heritable platelet disorder (HPD). Acquired disorders such as immune thrombocytopenia and drug-induced platelet dysfunction are not covered.
Since the previous guideline there have been significant advances in the clinical assessment of HPD. For example, bleeding assessment tools have been developed to standardise clinical evaluation and provide a quantitative analysis of bleeding symptoms. A major laboratory advance has been in the use of high-throughput sequencing which is now available in routine clinical practice in the UK. As a result there has been a large increase in distinct HPD with a better understanding of their underlying molecular basis and clinical effects. While these are individually rare disorders, collectively HPD comprise 10% of registered cases in the National Haemophilia Database, the fourth most common group of disorders after von Willebrand disease, haemophilia A and factor XI deficiency.
This presentation will focus on the key recommendations for the laboratory diagnosis of HPD and cover standards for aggregometry, assessment of platelet count and size, point of care testing, quality assurance and genomic testing.
Sponsored by Siemens Healthineers
Speakers
Dr Keith Gomez
British Society for Haematology Guidelines – laboratory assays
British Society for Haematology Guidelines – laboratory assays
Haematology
Learning outcomes
Delegates attending this presentation will gain knowledge on the recommendations from the BSH guideline writing group on various aspects including:
- Preanalytical variables and their effects on haemostasis tests
- Recommendations for assays to use when investigating factor deficiencies, and requirements for these assays including assay design.
- Recommendations on which assays to perform for thrombophilia testing.
- Considerations for quality assurance, including internal quality control and external quality assessment.
Abstract
The British Society for Haematology guideline committees are made up of expert haematology consultants and scientists from across the UK. They provide up to date guidance on the diagnosis and treatment of haematological disease. Three levels of report are produced depending on the available published evidence. Guidelines are evidence based with a full literature search generated from a convened writing group, Good Practice Papers recommend good practice in areas where less robust evidence is available to gain a degree of consensus and Position Papers provide adoption/adaptation of non-UK evidence-based guidance for the UK.
‘Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis’ was published in 2020 during lockdown and provides an update and amalgamation of 2 previous guidelines on haemostasis laboratory assays. This presentation will give a brief overview of its key components and recommendations using real world examples.
Broad subject areas covered include pre-analytical variables impacting blood collection, sample handling and storage and preparation as well as factors affecting assay construction, calibration, and control. The techniques discussed are then reviewed in the context of the investigation and monitoring of bleeding tendencies including fibrinogen estimation, awareness of reagent sensitivities to new haemophilia treatment options and the detection of acquired inhibitors. Finally, techniques and recommendations are made for the investigation of a thrombotic tendency concluding with guidelines for the diagnosis of the microangiopathy (TMA) Thrombotic Thrombocytopaenia Purpura (TTP).
Sponsored by Siemens Healthineers
Speakers
Peter Baker
Chimeric Antigen Receptor Therapy (CAR-T) for treatment of haematological malignancies
Chimeric Antigen Receptor Therapy (CAR-T) for treatment of haematological malignancies
Haematology
Learning outcomes
Delegates attending this presentation will:
- Gain a greater understanding CAR-T therapy
- Develop an awareness of the advantages of the therapy
- Understand some of the technical aspects of the therapy
Abstract
Chimeric antigen receptor (CAR) therapy has revolutionised the treatment of B cell malignancies and it is expected to extend its benefits to other tumours. There are currently five products approved for B cell lymphomas and plasma cell neoplasm and dozens in development for other haematological malignancies and solid tumours.
This lecture will offer an overview of the biology underpinning CAR therapies, the current products and challenges, the future of CAR therapies in combination with other modalities of treatment and how the experience in haematological conditions can help with the development of CARs for solid tumours and even non-oncological diseases.
Sponsored by Siemens Healthineers
Immunophenotyping
P.Knowlesi
P.Knowlesi
Haematology
Learning outcomes
Through the discussion of a patient case study that attended the Trust, delegates will:
- Understand the Pre-analytical, analytical and post analytical processes involved in a malaria request
- Learn about the morphological features of P.Knowlesi
- Have an understanding of the clinical presentation, treatment and clinical management of a patient with P.Knowlesi
Sponsored by
EQA Governance – the road ahead for the UK
EQA Governance – the road ahead for the UK
Haematology
Abstract
Healthcare Scientists and Pathology laboratories are at the heart of patient care. Patient safety is paramount to our work, and high clinical standards, embedded into a strong safety culture within the laboratory is vital. This is further augmented by the comprehensive application of prioritising learning and continuous improvement, open and transparent collaboration, and taking clear and proactive action to protect patients when safety doesn’t improve within a system.
The Royal College of Pathologists (RCPath) is leading a review of technical external quality assurance (EQA). This two-year programme has been produced with the aim to develop a robust framework for the system wide governance and oversight of EQA to ensure high standards in quality management, embed patient safety into pathology, ensure excellence in pathology output and support safe, high quality patient care across the health service. In addition, the programme aims to produce a sustainable funding mechanism from financial contributions from the relevant EQA scheme providers, based on openness, transparency and fairness.
The programme delivery plan includes: 1) Developing and implementing a robust multi-stakeholder governance and assurance framework incorporating new developments in systems governance, pathology service provision and EQA. 2) Agreeing and implementing a consistent approach to identifying and responding to poor performance. 3) Developing systems, practices and policies to share learning relating to quality management, continuous quality improvement and assurance of pathology results with service providers, manufacturers, professional societies and oversight bodies. 4) Strengthening collaboration with our external/regulatory partners across health services in the UK.
The EQA Oversight Board provides a collective oversight and assurance (scrutiny function provided by EQA Stakeholder forum) to the programme delivery plan, defined by the workstreams to operationalise.
Sponsored by Siemens Healthineers
Speakers
Dr Philip Monaghan FRCPath
Cytospin case studies
Cytospin case studies
Haematology
Learning outcomes
Through a discussion based on case studies found in the Trust delegates will:
- Understand what cytospins are.
- Learn about types of fluids that may be examined.
- Understand their role in the diagnosis and monitoring of haematological malignancy.
Abstract
An introduction to cytospins, what they are, the specimen types that we might use and how we obtain them.
Also includes a selection of cytospin cases that demonstrate how cytospins can aid in the diagnosis of infection, and haematological and non-haematological malignancy.
Sponsored by Siemens Healthineers
Speakers
Nicki Lawrence
Peritoneal dialysate fluid – testing for peritonitis
Peritoneal dialysate fluid – testing for peritonitis
Haematology
Learning outcomes
Through an interactive presentation based on case studies found in the Trust delegates will:
- Understand the methodology used behind the test.
Abstract
Peritonitis is a potentially life-threatening infection which can affect patients on peritoneal dialysis; rapid diagnosis is required to improve patient outcomes. Peritoneal dialysate fluid testing using the Advia 2120i was validated for use at Royal Stoke University Hospital in 2019, dramatically reducing the testing turnaround time.
This talk will explore how this was done, maximising the equipment already available to the lab, and the benefits of research for Biomedical Scientists.
Sponsored by Siemens Healthineers
Speakers
Aimee Pinnington
Hall 4 Programme
The importance of a thorough complaints investigation
New ISO risk and safety standards
Covid-19: the safety considerations associated with diagnostic testing and the vaccine response
Covid-19: the safety considerations associated with diagnostic testing and the vaccine response
Hall 4 Programme
Abstract
The Microbiology and Biotechnology team in HSE’s Chemicals, Explosives and Microbiological Hazards Division (CEMHD) is a team of specialist inspectors. The unit is responsible for the regulation of premises deliberately working with high-hazard microorganisms and genetically modified organisms that affect humans, animals and the environment across Great Britain. The range of work is hugely diverse, from regulation of laboratories in the NHS sector to novel molecular techniques for producing genetically modified organisms in academia.
Unsurprisingly, given the team’s regulatory functions, the COVID-19 pandemic has been a busy time. What followed in early 2020 was unprecedented and marked the start of a sustained period where the team provided a critical role in truly exceptional and challenging circumstances. The microbiology team went the extra mile to facilitate the government response to the pandemic while also ensuring that worker safety was not compromised.
In a fast-moving, politically sensitive situation the specialist team were required to make some difficult regulatory decisions against the back-drop of the emerging scientific evidence of the virus. The unit worked alongside experts in the sector to achieve a pragmatic and proportionate way forward whilst maintaining a firm regulatory stance to gain assurances that the safe systems of work and procedural controls in place provided adequate protection for those carrying out work with the virus.
The presentation will provide the audience an insight into the range of work carried out by the team in order to support the Governments diagnostic testing strategy, the advent of large scale diagnostic facilities never before seen on the UK and the supporting role HSE played in vaccine development and testing. The pandemic highlighted the range of work carried out by the team and the important and unique contribution that HSE made within government in this specialist area.
Speakers
Vin Poran
Introducing the PATHFAST™ - Emergency Marker High Sensitivity Troponin I assay into the Emergency Department
Influenza-like-Illness testing and its importance as SARS-CoV-2 moves from pandemic to endemic
The next revolution in infectious disease testing - integrating prognosis and diagnosis by reading the host response
East Kent Hospital inactivate SARS-CoV-2 in 60secs, revolutionising their workflow processes.
Preparing to pass the HSD
Preparing to pass the HSD
Hall 4 Programme
Abstract
The Higher Specialist Diploma (HSD) is the main route for gaining Fellowship (FIBMS) status of the IBMS.
This session will provide an overview of the qualification, outlining who it is aimed at, and what successful candidates will be able to do as a result of achieving the qualification. It will explain the portfolio requirements and the nature and structure of the exams. It will then provide advice and guidance on these two elements of the qualification and what candidates can do in order to put themselves in the best position to achieve the qualification.
Speakers
Chris Ward
Online learning – how to make it work for you
Online learning – how to make it work for you
Hall 4 Programme
Abstract
Online learning has become more prevalent in Biomedical Science education in recent years, even more so with the effect of the pandemic on colleges and universities.
This presentation will explore the different types of online learning currently in use and how to get the best out of them as both a learner and a manager.
Speakers
Dr Victoria Bradley
Planning and delivering laboratory training
The IBMS Registration Training Portfolio – everything you need to know
Portfolio evidence: the good, the bad and the totally avoid
Modules: a new approach to Specialist Portfolio training
How green is your laboratory – Embedding sustainability into practice?
Clinical informatics: the importance and impact for pathology
Clinical informatics: the importance and impact for pathology
Hall 4 Programme
Abstract
Clinical Informatics is the application of data and information technology to improve patient and population health, care and wellbeing outcomes, and to advance treatment and the delivery of personalised, coordinated support from health and social care.
This talk aims to show why Clinical Informatics is important for pathology and why pathology is important for clinical informatics. The talk will briefly cover, Governance – CCIOs Caldecott etc, education/professional standards, pathology messaging, digital diagnostic connectivity and interoperability, other uses of data, AI and machine learning.
Speakers
Robert Simpson
The National Genomics Test Directory and its implications for cellular pathology laboratories
Development of the Biomedical Scientist workforce in molecular pathology
How genomics is helping to revolutionise cancer care: integration of pathology and genomics in the NHS
Diploma of Expert Practice in Histological Dissection
Diploma of Expert Practice in Histological Dissection
Hall 4 Programme
Abstract
The session will provide an overview of the Diploma of Expert Practice (DEP) in Histological Dissection qualification, outlining who it is aimed at and the portfolio and examination structure.
The session will primarily focus on the portfolio requirements of the qualification providing advice and guidance on what should be included so that it is likely to be judged as a pass and how it can be compiled to ensure that it is easy for the examiners to assess it.
Speakers
Chris Ward
Immunology
Hereditary angioedema
Hereditary angioedema
Immunology
Learning outcomes
Delegates will:
Understand the pathophysiology, clinical presentation, laboratory diagnostics and management of hereditary angioedema.
Abstract
Hereditary angioedema is a rare inherited disorder which results in recurrent episodes of swelling which can affect various parts of the body including the airway, face, limbs and intestinal tract. Historically, deficiency in C1 inhibitor due to mutations in the SERPING1 gene have been identified as a cause of hereditary angioedema. However, more recently, cases of hereditary angioedema with normal C1 inhibitor have been described, with subsequent identification of several different genetic mutations to account for this.
Delayed diagnosis of hereditary angioedema in patients is not uncommon. If C1 inhibitor deficiency is suspected, tests for complement C4 and C1 inhibitor should be undertaken. It is important to make the diagnosis as the condition can be life-threatening and conventional treatments for allergic swelling (e.g. adrenaline, steroids and antihistamines and corticosteroids) are ineffective in hereditary angioedema.
This presentation will cover the pathophysiology, clinical presentation, laboratory diagnostics and management of hereditary angioedema.
Sponsored by NHS South West London Pathology
Allergy component refresher
Autoimmunity testing on a mutidisciplinary track
Choosing wisely – an immunology perspective
Choosing wisely – an immunology perspective
Immunology
Learning outcomes
This presentation will give:
- An overview of choosing wisely.
- The relevant aspects for immunology.
- Information on the audits and outcomes from Barts Health.
Abstract
Choosing Wisely UK is part of a global initiative aimed at improving conversations between patients and their healthcare professionals. Choosing Wisely UK was launched in 2016 by the Academy of Medical Royal Colleges as a way to identify tests of questionable value meaning that the appropriateness of their use should be discussed before being carried out. This work has since been superseded by other initiatives such as Evidence based Interventions and rethinking medicine.
This presentation will give:
- An overview of choosing wisely.
- The relevant aspects for immunology.
- Information on the audits and outcomes from Barts Health
Sponsored by NHS South West London Pathology
Speakers
Chris Scott
Type I interferon regulation in Systemic Lupus Erythematosus and its wider implications in autoimmune disease
Type I interferon regulation in Systemic Lupus Erythematosus and its wider implications in autoimmune disease
Immunology
Abstract
Type I interferons (IFNs) have been known to have a crucial role in the pathogenesis of systemic lupus erythematosus (SLE) for decades. Recent evidence has overturned several long-held assumptions about how IFNs are regulated and cause pathology. For instance, plasmacytoid dendritic cells (pDCs), the main type I IFN producing cells, are proven to be functionally impaired, incapable of inducing adequate immune responses, even in individuals with benign preclinical autoimmunity. This has offered a new view of lupus pathogenesis that answers longstanding clinical dilemmas.
More data show the greater importance of non-haematopoietic cellular sources of type I IFNs such as keratinocytes, renal tubular cells, glial cells and synovial stromal cells, as well as local responses to type I IFNs within these tissues. These local effects are found not only in inflamed target organs in established SLE, but also in histologically normal skin during asymptomatic preclinical phases, suggesting a role in disease initiation.
Therefore, the development of biomarkers to characterise the complex type I IFN system, and monitor recently-licensed IFN-blocking therapies are of pivotal importance. These novel approaches in SLE may lead to disease reclassification and preventative strategies in preclinical phases.
Sponsored by NHS South West London Pathology
Speakers
Dr Anthony Psarras
Neuroscience laboratories services
Neuroscience laboratories services
Immunology
Learning outcomes
Delegates will learn how:
- The Neuroscience Laboratories support a specialist tertiary Neurology and Neurosurgery Hospital and the wider population.
- How we work as a cross discipline team to deliver our Neuropathology, Neuroimmunology and Neurobiochemistry services.
- What the risks and opportunities are of being such a specialist service.
Abstract
The Neuroscience Laboratories are part of The Walton Centre NHS Foundation Trust, a unique specialist tertiary neurology and neurosurgical Hospital providing care for a population of 3.3 million across the North West of England and North Wales. Neurobiochemistry, Neuroimmunology and Neuropathology services are provided by a team of twenty-one highly skilled staff comprised of neuropathologists, clinical scientists, biomedical scientists, associate practitioners with medical laboratory assistant and secretarial support.
They work as a cross discipline team to aid in the diagnosis of tumours and neurological conditions. They have established a neuroscience biobank –The Liverpool Neuroscience Biobank at The Walton Centre, which supports translational research with local health partners. This presentation will describe the services provided and the unique challenges they face as a specialist service.
Sponsored by NHS South West London Pathology
Testing for the investigation of myasthenia gravis
Testing for the investigation of myasthenia gravis
Immunology
Learning outcomes
Delegates will understand:
- Multiple antibody targets exist for the pathophysiology of myasthenia gravis
- Multiple techniques exist for the measurement of myasthenia gravis
- Choosing the correct assay for the patient and testing for analytes in the right order, depending on the clinical picture, is important to maintain testing efficiency.
Abstract
Myasthenia Gravis is a condition that warrants proactive screening when suspected. Although initially there was limited availability of testing for ACHR antibodies (the primary cause of MG), current testing can be performed by a variety of platforms and additional markers are also available.
This session aims to outline the different targets for the immune system in myasthenia gravis and to highlight the different clinical presentations seen with them. It will then summarise the different options for testing and the potential to use them in algorithmic order.
Sponsored by NHS South West London Pathology
Myositis antibodies: Are we missing something?
Myositis antibodies: Are we missing something?
Immunology
Learning outcomes
Delegates will gain an understanding of:
- The range and clinical utility of myositis antibodies including multiple sensitivities.
- The utility of myositis associated antibodies in identifying patients who require cascade to myositis panels.
- Statin induced myositis and HMGCoA antibodies.
- The prevalence of antibodies in a north east Scottish population.
Sponsored by NHS South West London Pathology
Autoimmune bullous dermatoses: beyond the green screen
Autoimmune bullous dermatoses: beyond the green screen
Immunology
Learning outcomes
Delegates will gain an understanding of:
- The principles underlying immunobullous disease pathology
- Current lab diagnostic methodologies for these diseases
- Typical results and diagnostic interpretation
Abstract
This presentation will provide a brief overview of autoimmune bullous diseases, focusing on their pathological basis, through the targeting of epithelial desmosomal and hemi-desmosomal components by autoreactive antibodies in pemphigus and pemphigoid diseases, respectively, the current sub-classifications of these disorders and the lab techniques used to diagnose and monitor these diseases.
The use of both direct immunofluorescence analysis of patient tissue and indirect immunofluorescence utilising serum samples and a variety of tissue substrates, including normal and salt-split human skin and monkey oesophagus, in addition to specific ELISA testing for antibodies against desmogleins 1 and 3, BP180, BP230 and collagen VII will be described, with reference to typical results seen, interpretation and practical troubleshooting.
Sponsored by NHS South West London Pathology
Speakers
Dr John Mee
Serological testing for immune-mediated lung disease
Serological testing for immune-mediated lung disease
Immunology
Learning objectives
- Overview of the various forms of hypersensitivity pneumonitis and their primary triggers as well as the spectrum of Aspergillus lung disease.
- A summary of the diagnostic methods used for the investigation of these rare disorders including their relative merits such as diagnostic performance characteristics, EQA performance, guideline recommendations etc.
- Review a selection of clinical example cases from our experience as a reference centre.
Abstract
Serological analysis (IgG and precipitins testing) plays an important role in the diagnosis of various extrinsic/environmental immune-mediated lung diseases. These disorders include the various forms of hypersensitivity pneumonitis (e.g. bird breeder’s lung, farmer’s lung etc) as well as the spectrum of Aspergillus and other fungal lung diseases. The laboratory methods available to measure microbial antibodies include immunoassays (ELISA, FEIA) as well as antibody precipitation techniques including double diffusion and counter-immunoelectrophoresis.
The aim of this session is to provide a clinical overview of some of the forms of extrinsic immune lung disease as well as the utility of laboratory methods in their investigation and monitoring.
Sponsored by NHS South West London Pathology
Speakers
Dr Adrian Heaps
Human leucocyte antigen epitopes
Human leucocyte antigen epitopes
Immunology
Learning outcomes
Delegates attending this presentation will:
- Understand the concept of HLA epitopes
- Be aware of the software tools available to determine HLA epitope profiles
- Understand how HLA epitopes are applied in clinical practice
Sponsored by NHS South West London Pathology
Clinical applications of the predicted indirectly recognisable HLA epitopes (PIRCHE) software tool in solid organ and bone marrow transplant
Cell and Gene therapy: Manufacturing support to the NHS
Cell and Gene therapy: Manufacturing support to the NHS
Immunology
Learning outcomes
Delegates attending this presentation will:
- Be able to describe the range of cell therapies available for clinical use
- Understand issues related to the production of cell therapies
- Have knowledge on the clinical applications of cell therapies
Abstract
Cell and Gene Therapies are rapidly expanding to support a variety of patients. The manufacture and supply of Advanced Therapeutic Medicinal Products and Investigational Medicinal Products is a key component of personalised medicine development and crucial for developing NHS strategies. To support this NHS Blood and Transplant (NHSBT) Cellular and Molecular Therapies division works in collaboration with commercial, academic and NHS projects to manufacture products under Good Manufacturing Practise (GMP) conditions for a variety of clinical trials and clinical applications.
This presentation will give an overview of the requirements and considerations for undergoing tech transfer from research into GMP demonstrating the role the NHS can play in the future of this exciting field.
Sponsored by NHS South West London Pathology
Speakers
Dr Katy Latham
Genomics of inborn errors of immunity - from rare variants to clinically actionable findings
Genomics of inborn errors of immunity - from rare variants to clinically actionable findings
Immunology
Learning outcomes
Delegates attending this presentation will:
- Understand the basics of genetic testing
- Understand the role of molecular / genetic testing in diagnosis of primary immunodeficiencies
- Learn about the use of registries of genetic data
Abstract
Advances in genomic medicine are helping to shorten the diagnostic odyssey for many patients with inborn errors of immunity but key challenges remain.
This case-based talk will place genomic testing in the context of an overall diagnostic approach that includes clinical and laboratory phenotyping, and often requires functional validation of genetic findings.
Sponsored by NHS South West London Pathology
Cryoprotein analysis – a UK NEQAS update
Investigating cryoproteins – are we offering the best service possible?
Investigating cryoproteins – are we offering the best service possible?
Immunology
Learning outcomes
This presentation will include:
- Reminder of types of cryoglobulin and requirements for effective analysis
- Discussion of importance of cryofibrinogen and testing plasma samples as well as serum samples for cryoprotein studies.
- Presentation of relevant clinical cases.
Abstract
The investigation of cryoglobulins is a technically challenging lab test, requiring a stringent, validated process for sample collection. Published protocols agree on the vital importance of collecting, clotting and separating samples in a way that maintains samples at 37C but this remains a challenging area, particularly when labs are serving a network of healthcare providers. The impact of pre-analytical factors on cryoglobulin results is likely to vary depending on the individual cryoprotein.
Cryoglobulins can be associated with B cell malignancy, autoimmune disease and some viral infections, particularly hepatitis viruses. The detection and typing of cryoglobulins can provide a valuable clue to the underlying pathology driving a patient’s symptoms, and help direct patient treatment.
This talk will use example cases to explore the variation in the appearance and behaviour of cryoglobulins, the factors that can confound result interpretation, and the impact of cryoprotein studies on patient care.
Sponsored by NHS South West London Pathology
Speakers
Dr Rachel Wheeler
Assay trouble shooting – case study
Goodpastures case study
Goodpastures case study
Immunology
Learning outcomes
Through the discussion of a case study delegates will learn about:
- Patient presentation
- Routine test results and specialised test results
- Diagnosis, treatment and monitoring
- Outcome for the patient.
- Epidemiology, pathogenesis, diagnosis, treatment and outcomes.
Sponsored by NHS South West London Pathology
Breaking news in Immunology
Myasthenia gravis - a patient's perspective
Myasthenia gravis - a patient's perspective
Immunology
Abstract
A talk by Rashmi Rungta, Trustee of Myaware, a charity supporting people living with an invisible and unpredictable auto-immune condition called Myasthenia Gravis.
Rashmi has worked hard to convert her weaknesses into strengths and equipped herself with the right tools to further her career and take on new challenges. She has been on the senior management team and has built and led teams of over 50, for large MNCs such as Fujitsu Consulting, ITC Infotech, Siebel, Cap Gemini, Churchill, Deloitte. Her clients have included FTSE 100 industry leading like Unilever, Harley Davidson, BAT, USAID, Telia Sonera, IBM and so on.
Rashmi has lived her entire life with MG as she was an extremely rare case of developing the condition as a 6-month-old baby and was a research patient at NIH, Bethesda at the age of 10.
She will give a patient’s perspective on this disease in the hope of raising awareness of the condition as well as highlighting the consequences of the treatments and the absence of it. Additionally, she hopes that this will lead to earlier diagnosis in the future, which should help to reduce the severity of the illness. She would like to make a case for cross-border collaboration on the ongoing research.
Her presentation will focus on:
- Early signs to the ongoing management of MG throughout her life, the physical and mental consequences and the unpredictable relapses of the condition that have occurred.
- Treatment, including medications.
- How being immunosuppressed has affected her life, especially since the arrival of Covid-19.
- Challenges and Successes To quote Chris Scott who contacted her through the website “It’s the patient story and your journey to diagnosis and living with Pemphigoid which we as scientists are interested in. Sometimes in the lab we become a bit divorced from the job we are doing, and this makes us come a bit closer to why we do what we do in the lab”.
Sponsored by Abbott
Sponsored by NHS South West London Pathology
Speakers
Rashmi Rungta
Life after the 467, a tale of Bullous Pemphigoid
Life after the 467, a tale of Bullous Pemphigoid
Immunology
Abstract
A talk by Ingrid Thompson, website manager for Pemfriendsuk.co.uk, a site dedicated to Support for patients with Pemphigus and Pemphigoid and their carers.
Ingrid is a sufferer of the chronic autoimmune blistering skin disease Bullous Pemphigoid.
She is giving a patient perspective on this disease in the hope of raising awareness of the condition as well as highlighting the consequences of the treatments, especially steroids, which saved her life, but have left her with side effects. She is involved as a patient in several projects, including a PSP conducted by the Centre of Evidence Based Dermatology in Nottingham and developing the guidelines for the management of Bullous Pemphigoid with the British Association of Dermatologists.
Her talk will tell her story from early signs to the extreme rapidity of the blister development once they started to erupt. She will tell you a bit about her treatment, including medications and living with the disease.
Her presentation includes some graphic images of her blisters as they developed which illustrate how severe the disease can be and that it can be fatal if not treated properly.
She will also tell you how being immunosuppressed has affected her life, especially since the arrival of Covid-19.
Ingrid wants to raise awareness of this disease and hopes this will lead to earlier diagnosis in the future which should help to reduce the severity of the illness.
To quote Chris Scott who contacted her through the website “It’s the patient story and your journey to diagnosis and living with Pemphigoid which we as scientists are interested in. Sometimes in the lab we become a bit divorced from the job we are doing, and this makes us come a bit closer to why we do what we do in the lab”
She is looking forward to seeing you on the 17th March
Sponsored by NHS South West London Pathology
Patient experience – primary immunodeficiency
Patient experience – primary immunodeficiency
Immunology
Abstract
In 2006, at the age of 7, Emily was diagnosed with Common Variable Immunodeficiency. Although Emily had had health issues before, there had been no real indication that she was suffering from a chronic disease, apart from a feeling within the family that something wasn’t “quite right”.
Now, Emily has had a successful academic career and in 6 months time, will be joining one of the world’s foremost management consultancies. Emily’s mother will be talking about Emily’s life – the years leading up to diagnosis, the progress of the symptoms, the impact her condition has had on Emily, her education and development as well as the effect on her family of having a child with a chronic and impactful medical condition.
Emily’s mother will also speak about living with a primary immunodeficiency during a pandemic, and now that restrictions are coming to an end, the reality of how that affects those who are still extremely vulnerable to infection.
Sponsored by NHS South West London Pathology
Speakers
Clare Brailsford
Laboratory Management
Decision making in a crisis situation
Decision making in a crisis situation
Laboratory Management
Abstract
Based on 35 years leading and being led in some of the most demanding of environments, the talk will look at what it takes to lead effectively in a crisis. It will examine areas such as how leaders build and sustain a mutual contract of trust with those they lead; the importance of leadership presence; resilience, both personal and organisational; the power of teams and how to empower your people to be able to step up and make decisions under pressure.
The presentation will use vignettes and examples from military operations over the past 30 years, as well as suggesting how those lessons might be translated into the civilian environment.
Sponsored by Beckman Coulter
Speakers
Major General (Retired) Paul Nanson CB CBE
Positive onboarding – making staff induction an investment for success
Positive onboarding – making staff induction an investment for success
Laboratory Management
Abstract
This session recognises that there is only one induction / onboarding process for anyone entering a new organisation and department. This is a crucial aspect of entering the workplace and sets the scene for the future perceptions of the new employee.
The session aims to provide insights to make induction a positive, enjoyable and valuable process with consideration of the psychological aspects of induction, integration into the organisational culture and tips on successful induction programmes.
Sponsored by Beckman Coulter
Speakers
Sue Alexander MSc MSc MBA CSci FIBMS CBiol FRSB MIHM MCQI CQP
Lead, follow or get out of the way
Applying organisation values to your leadership
Applying organisation values to your leadership
Laboratory Management
Abstract
This session will explore the relationship between organisational values, leadership and culture and complements the Positive Onboarding session. It will also explore the concept of personal and organisational values, and how leaders influence and transmit values. It will discuss what values based leadership encompasses and will encourage reflection and discussion on what is needed to lead with values.
Sponsored by Beckman Coulter
Speakers
Sue Alexander MSc MSc MBA CSci FIBMS CBiol FRSB MIHM MCQI CQP
Pre-empting problems – may the workforce be with you
Pre-empting problems – may the workforce be with you
Laboratory Management
Abstract
"An organisation's most valuable asset is its employees". It's a phrase we've all heard so many times before that it has become a platitude. It does, however, remain true. Aside from the fact that your service simply couldn't run without them, staffing costs are likely to be the single biggest financial expenditure in your organisation. So how often do our management practices genuinely invest in the individuals responsible for delivering our pathology services?
When success is measured against turnaround times and test repertoire, our go to solutions can be reactive and lacking in consideration of human factors. Even our most common people metrics (absence rates, turnover, appraisal completion) can lead us down a road of quick fixes.
The business case for staff engagement, health and wellbeing is clear. It has been widely demonstrated that an engaged workforce can lead to higher productivity, lower absenteeism and improved morale. The bottom line is that it results in a better experience for our patients and service users. So why aren't all our managers and leaders focussed on this more sustainable approach to improving performance? The truth is, it's not easy. It can't be done overnight. But it is worth it.
We'll consider how we can better use the metrics we have at our fingertips to pre-empt potentially costly people challenges and improve performance, and review some tools and techniques for filling in any blanks. We'll also examine how managers can tap into their "soft" skills to improve engagement and what leaders can do to support this approach.
Sponsored by Beckman Coulter
Speakers
Charley Frampton
It's okay not to cope
It's okay not to cope
Laboratory Management
Abstract
The Covid-19 pandemic placed unprecedented demand on medical services as well as on the ability to access and make use of ways to cope and look after ourselves and others. As the pandemic progressed over such a significant period, it is not surprising that people may have found coping difficult. Whilst the imminent pressures of the pandemic have reduced, the challenges to NHS services have not.
'It's okay not to cope' will aim to offer a theoretical framework for the challenges of coping through the pandemic and beyond. This will utilise ideas from compassion-focussed theory which considers the impact of our evolutionary functions on our behaviours and how our early experiences can shape how we treat ourselves and others.
The talk will include an overview of compassion-focussed approaches to understanding behaviour, suggestions for ways in which we can help ourselves to develop healthy coping strategies and resilience, and how we can try to rest more effectively.
Speakers
Dr Sarah Titchen
The exit interview – a meaningful goodbye
The exit interview – a meaningful goodbye
Laboratory Management
Abstract
What is the point of an exit interview? Perceptions in general are that it is a waste of time, but we still do them in various forms - why?
This talk will discuss and show that they can in fact be a useful tool for highlighting issues within an organisation and a catalyst for change.
Sponsored by Beckman Coulter
The importance of good laboratory design on staff health and wellbeing
Medical Microbiology
What the future holds in Microbiology - precision AMR project
What the future holds in Microbiology - precision AMR project
Medical Microbiology
Abstract
Antimicrobial Resistance (AMR) is an ever-growing problem and is one of the biggest challenges that face us all today. Research and improvements in diagnostic microbiology is key to helping improving AMR and antimicrobial stewardship.
Without working to resolve AMR, there is likely to be poor clinical outcomes for patients. In 2019 funding was granted for a major project called Precision AMR. This project worked to break down barriers in AMR research. Develop new diagnostic techniques. Improve the quality and speed of results to wards in hospitals. Working to change clinical management to help reduce AMR. Changing prescribing behaviours in medication for AMR infections.
Using data science to support AMR research. Understanding factors that lead to AMR through audit and service valuation. Lastly using engagement as a tool to raise awareness of AMR with other healthcare workers and patients to know about the threat that AMR brings.
This presentation will discuss the outcomes of the precision AMR project and will also look at what the future holds for diagnostic microbiology and AMR.
Sponsored by Eurobio Scientific
Speakers
Francis Yongblah
Narrative Authorising -an extend role for biomedical scientists
Narrative Authorising -an extend role for biomedical scientists
Medical Microbiology
Abstract
Currently, seven Clinical Biomedical Scientists actively engage in Narrative Reporting in Wales. Narratice Reporting introduces the patient story into the formal microbiology report, taking it from a cold statement of scientific findings about a specimen received by the laboratory, to a document that explains what these scientific findings might mean in the context of the requesting information provided and any other intelligence already available to the person reporting the results.
The approach acknowledges that healthcare is a complex adaptive system and with narrative nudges, behavioural changes are induced in our service users. As a result, for two health boards in Wales this had resulted in:
- Improved clinical information on the requests
- A responsive report that users acknowledge in laboratory surveys and commended in our UKAS assessment
- A reduction in sample numbers arriving in the laboratory (66,000 per annum when last examined)
- Early indications that antimicrobial resistance rises have stabilised
Sponsored by Eurobio Scientific
by:
Advanced Clinical Practice in Microbiology
Long term Quality Improvement in Microbiology
Methods for the isolation of nontuberculous mycobacteria (NTM) from respiratory samples and the environment
Methods for the isolation of nontuberculous mycobacteria (NTM) from respiratory samples and the environment
Medical Microbiology
Abstract
Nontuberculous mycobacteria (NTM) are increasingly implicated as an important cause of respiratory infection in individuals with cystic fibrosis (CF) and other underlying lung diseases. For diagnosis, international guidelines recommend that sputum is decontaminated with alkali prior to culture using both solid and liquid culture media. Chemical decontamination is also recommended for the isolation of NTM from environmental samples (e.g. water samples). Such decontamination can lead to a severe reduction in the viability of NTM, and rapidly-growing species (e.g. Mycobacterium abscessus) are particularly affected. An alternative approach for isolation of NTM is the use of a highly selective culture medium (e.g. RGM medium) without the use of chemical decontamination. This presentation will review the advantages and disadvantages of culture using RGM medium versus culture using conventional methods for both respiratory samples and environmental samples.
Recently published data claim that the use of 2% sodium hydroxide (NaOH) for decontamination leads to an 87% average decrease in the number of viable M. abscessus in sputum samples, with 4% NaOH causing a 98% reduction. This is reflected by several studies from the UK and the United States which show that M. abscessus can be detected in significantly more respiratory samples when decontamination is avoided. The viability (and recovery) of slow growing species such as M. avium complex is less affected by decontamination. One drawback of direct culture (without decontamination), is the recovery of small numbers of commensal NTM that have little clinical significance in respiratory infection (e.g. M. chelonae). For processing water samples, the use of direct culture (without decontamination) is especially useful leading to the effective inhibition of virtually all non-mycobacteria and substantial savings in the time taken to process samples and the isolates that are recovered.
Sponsored by Eurobio Scientific
Speakers
Professor John Perry PhD, DSc
HSST experience in Microbiology
HSST experience in Microbiology
Medical Microbiology
Abstract
A brief overview of the higher specialist scientific training (HSST) programme for Medical Microbiology, exploring the content of the course from the perspective of a trainee.
A must see talk for both scientists and service managers considering this route of progression. Expect honesty, pearls of wisdom and enthusiasm for a programme that offers a clinical training pathway for scientists.
Sponsored by Eurobio Scientific
Speakers
Phillipa Burns MSc FIBMS CSci DipRCPath
A drive for change: a Queen's Medical Centre perspective
A drive for change: a Queen's Medical Centre perspective
Medical Microbiology
Abstract
In 2021 the Clinical Microbiology department at Nottingham University Hospitals moved to a 24/7 service. The catalyst for this change, as has been the case for a lot of things over the last 12-24 months, was the pandemic however multiple factors would have suggested that one way or another this change was inevitable. The impact on the workforce has been significant and multi-faceted and the planning that has gone in to preparing for the change proved to be a daunting and exhausting managerial undertaking. Workforce planning has been a key element in preparing for the change and was a key topic in all conversations on the matter from the very start. We tried our best to have a clear idea of what staff we need and at what levels but it was clear we were dealing with a lot of unknowns in many different guises.
The recruitment process was extensive at all grades and even though successes have been experienced, the subsequent challenges continue to present themselves. We are in a brave new world for our service, but we are pushing forward with a positive mindset and a willingness to adapt to ensure the change is successful for the long term benefit of our patients.
Sponsored by Eurobio Scientific
From Acrophialophora to Zygosaccharomyces: Expanding the potential of the Bruker Biotyper for fungal identification
From Acrophialophora to Zygosaccharomyces: Expanding the potential of the Bruker Biotyper for fungal identification
Medical Microbiology
Abstract
Over the past decade, matrix-assisted laser desorption ionisation time of flight mass spectrometry (MALDI-TOF MS) has revolutionised the identification of microbes in clinical diagnostic laboratories. It's application to the identification of yeast is well documented and if adequate laboratory protocols are followed, is very successful. However, its use as a tool for the identification of filamentous fungi (moulds) is still the matter of some development. There is currently no standardised methodology for the processing of moulds for MALDI-TOF MS identification and the commercially available databases are severely lacking in both depth and active development especially within the context of rapidly evolving taxomnomic revision.
At the UKHSA National Mycology Reference Laboratory we have developed, and continue to curate, an expanding adjunctive database for the rapid identification of moulds using MALDI-TOF MS. This talk will share the experiences of handling fungi for MALDI-TOF MS and present an up to date overview of the work of the MRL to expand and improve the commercially available database for the Bruker Biotyper. There will also be hints and tips towards the most successful methods for application of MALDI-TOF MS to the identification of all fungi in the clinical diagnostic laboratory.
Sponsored by Eurobio Scientific
Speakers
Dr Mark Fraser
Rapid identification from blood cultures
Rapid identification from blood cultures
Medical Microbiology
Abstract
Prompt antimicrobial treatment is integral to the treatment of and recovery from sepsis. Providing appropriate therapy relies on the accurate identification of the causative organism(s), so a study was conducted to investigate the potential to improve the time taken to identify the organism(s). The Bruker Sepsityper method was tested against routine MALDI-TOF identification from culture to investigate whether earlier identification of bacteria by the Bruker Sepsityper could offer improvement to the service offered by the department.
Fluid from 100 positive blood culture bottles was tested using the Bruker Sepsityper methodology to determine the identification of any organism(s) present, and compared to routine MALDI-TOF identification from solid media culture. 99 of the 100 bottles tested yielded at least one organism from culture. 106 organisms were isolated in total; a mixture of 49 Gram-positive bacteria, 54 Gram-negative bacteria and three yeasts.
Of the 99 confirmed culture positive bottles, 92 gave an identification using the Sepsityper method. There were four instances of misidentification by Sepsityper compared to culture, all of which were cultures of Staphylococcus hominis misidentified as S. haemolyticus. 79 of the 99 positive bottles gave a species-level result by the Sepsityper method that matched the result from culture.
The Sepsityper method is much quicker with a mean of 2.18 hours to result compared to the current method from culture at 9.53 hours. Clinical interpretation revealed that there were no instances where an earlier identification result would have resulted in a change to patient management in this study, as the empirical treatment given was appropriate, but there is the potential for treatment intervention as a result of an earlier identification result.
Sponsored by Eurobio Scientific
Speakers
Robert Impey
The microbiome and mental health - potential future diagnostics in microbiology
The microbiome and mental health - potential future diagnostics in microbiology
Medical Microbiology
Learning outcomes
Through the discussion the literature analysing the connect between infection and neurosis, delegates will:
- Gain an understanding of the microbiome and its links with mental health.
- Be able to discuss the impact of faecal transplant on mental health.
Sponsored by Eurobio Scientific
Mapping the genomic architecture of COVID-19, a discovery that may aid in the fight against SARS-CoV-2 infection
Mapping the genomic architecture of COVID-19, a discovery that may aid in the fight against SARS-CoV-2 infection
Medical Microbiology
Learning outcomes
SARS-CoV-2 infection or severe COVID-19 symptoms were connected to a number of genome-wide significant loci. Several of these loci have been associated with inflammatory, autoimmune, and pulmonary illnesses. They could also help fight infections.
The quick discovery of novel host genetic factors connected to COVID-19 was made possible by a collaborative effort among biomedical scientists, clinicians, and bioinformatics. Global collaboration enables future genetic discoveries in pandemics and other human diseases.
Abstract
A person's genetic makeup influences their susceptibility to and reaction to viral infections. The severity of SARS-CoV-2 and COVID-19 illness is affected by environmental, clinical, and social factors. Host genetics may be Important It may be possible to relate modifiable environmental risk factors to SARS-CoV-2 infection and consequences by discovering host-specific genetic variables.
An international research network was established to assess the role of human genetics in SARS-CoV-2 and COVID-19 severity. SARS-CoV-2 infection or severe COVID-19 symptoms were connected to a number of genome-wide significant loci. Several of these loci have been associated with inflammatory, autoimmune, and pulmonary illnesses. They could also help fight infection.
The quick discovery of novel host genetic factors connected to COVID-19 was made possible by a collaborative effort among human genetic experts. Global collaboration enables future genetic discoveries in pandemics and other human diseases.
Sponsored by Eurobio Scientific
Speakers
Dr Yasser El-Sherbini
EUCAST update 2022
Antibiotic resistance spillover into wildlife - using birds of prey as signal species
Antibiotic resistance spillover into wildlife - using birds of prey as signal species
Medical Microbiology
Abstract
Antibiotics are possibly one of the most important medical innovations human science has developed. However, this also means we have to understand and tackle antibiotic resistance and this is an issue that has great importance in the ‘One Health’ context. We can no longer think of antibiotic resistance occurring in only the human or animal sector, so the potential for antibiotic resistance spill over into different settings needs to be considered.
This presentation considers the early findings of surveillance work looking into the potential for resistance patterns to drugs used in the human context being found in wild and captive raptors in the UK. Can these observations be usefully employed as markers of antibiotic resistance spill over into animals or does more work have to be done?
Sponsored by Eurobio Scientific
Whats new in mycology?
Whats new in mycology?
Medical Microbiology
Abstract
It is an exciting time to be working in medical mycology with an expanding array of quick turnaround diagnostic tools, an ever-increasing number of opportunistic pathogens, new patient groups in which they are encountered and some new and developmental therapies.
This presentation will start with an overview of COVID-19 fungal co-infections and will include discussion of emerging azole-resistance in Aspergillus fumigatus isolates including molecular detection methods, recently introduced lateral flow technology for the diagnosis of invasive aspergillosis and specific CHROMagar Candida 2 for the detection of Candida auris colonisation and infection. Some new and developmental antifungal agents will also be discussed.
There will also be a discussion of the increasing prevalence, diagnosis, and treatment of cutaneous lesions of the limbs in solid organ transplant recipients caused by Alternaria species.
Sponsored by Eurobio Scientific
Speakers
Professor Elizabeth Johnson PhD, FECMM
Invasive Magnusiomyces capitatus infection in a patient with neutropenic sepsis
Invasive Magnusiomyces capitatus infection in a patient with neutropenic sepsis
Medical Microbiology
Abstract
Magnusiomyces capitatus is an uncommon yeast that has undergone a number of taxonomic revisions and has been described as Blastoschizomyces capitatus, Geotrichum capitatum, Trichosporon capitatum and Dispodascus capitatus. M. capitatus can cause invasive infections among immunosuppressed patients especially those with hematologic disorders but can also infect other immunocompromised patients and infections are often associated with increased risk of dissemination and high mortality rates.
In addition, Magnusiomyces species, along with other arthoconidial yeasts, are intrinsically resistant to echinocandins which are often used as a first line therapy for invasive candidiasis. This discussion describes a dual Candida infection in a neutropenic patient and discusses the relevant clinical and laboratory findings inparticular with regard to M. capitatus
Sponsored by Eurobio Scientific
Anaerobes – latest update and important developments
The great and recurrent questions regarding Clostridioides difficile
The great and recurrent questions regarding Clostridioides difficile
Medical Microbiology
Abstract
With the successful incorporation of whole genome sequencing single nucleotide polymorphism (WGS SNP) analysis for C. difficile typing in Wales, our understanding of C. difficile colonisation and infection is increasing.
The launch of the Wales C. difficile Infection Focus Forum (WCDIFF) is helping health care professionals from multiple disciplines to assess and implement latest guidance and to share best practice from across the country, and further afield. During the presentation the latest findings from Welsh WGS SNP analysis and the WCDIFF will be shared and discussed.
Sponsored by Eurobio Scientific
Speakers
Michael Perry
Impact of HG3 organisms not being suspected from clinical resulting in processing at CL2
Impact of HG3 organisms not being suspected from clinical resulting in processing at CL2
Medical Microbiology
Abstract
Clinical information on request forms is utilised to direct additional testing that may be required for patients. Scrutiny by laboratory staff of this information additionally allows precautionary action to be undertaken if an organism is suspected to be classified above hazard group 2 resulting in processing or storage for transport at containment level 3.
This presentation reviews and discusses cases within the laboratory setting where the clinical information has not indicated the risk associated with the sample, resulting in those samples being processed at containment level 2.
Sponsored by Eurobio Scientific
Speakers
Michelle Peters
Microbiome–associated metabolites and the gut–brain axis
Microbiome–associated metabolites and the gut–brain axis
Medical Microbiology
Learning outcomes
Delegates attending this presentation will:
- Gain an understanding of what the gut–brain axis is.
- Learn how metabolites produced by gut bacteria can have systemic effects.
- Understand the potential medical implications of gut microbiome–brain interactions.
Abstract
The gut microbiota comprises bacteria, archaea, viruses, and lower and higher eukaryotes. Together, the gut microbiota and its mammalian host contribute to the gut microbiome, a symbiotic entity that exerts a strong influence on host health. A range of metabolites produced by the microbiota from the foods and drugs we ingest can be taken up from the gut via the hepatic portal vein to the liver, where they enter the circulation either unchanged or modified via hepatic enzymes.
As such, there is extensive microbial–host co-metabolism within mammalian systems. Circulating microbiome-associated metabolites interact with organs in the body, and it is widely recognized that they influence disease phenotypes in metabolic diseases. Lesser known is the effects these metabolites have on the gut–brain axis, representing the bidirectional communication that occurs between the central and enteric nervous systems.
This talk will highlight recent work demonstrating how microbiome-associated metabolites influence the gut–brain axis, with a special focus on studies showing a direct interaction of these metabolites with the mammalian blood–brain barrier and cognitive function.
Sponsored by Eurobio Scientific
Speakers
Professor Lesley Hoyles FRSB
Whole-genome sequencing in Microbiology
Whole-genome sequencing in Microbiology
Medical Microbiology
Abstract
Whole genome sequencing is increasingly being employed to improve microbial diagnostics and enhance pathogen surveillance in order to deliver better outcomes for patients.
Genomics is more than a typing tool. It offers an opportunity to redesign services and how diagnostics are delivered, while simultaneously providing an opportunity to improve efforts around pathogen surveillance and health protection. In essence, pathogen genomics offers opportunities to provide more precise healthcare from patient to population. The nature of genomic data also creates opportunities to move beyond narrow ways of examining pathogens, to considering the wider interplay of pathogen, host and environment.
Work to build accredited services and realise the potential of whole genome sequencing for microbiology is underway across the NHS. Here, I will share some of the work that is going in in Wales, showcasing the accredited services we already offer and the work that has been required to build these pathogen genomics services - some of which are global firsts. I will then move on to consider the potential of whole genome sequencing, concluding with a look forward, considering how pathogen genomics will change the way that we view pathogens and deliver services in the future.
Sponsored by Eurobio Scientific
Speakers
Professor Thomas Connor
Importance of oral microbiology
Importance of oral microbiology
Medical Microbiology
Abstract
An increase in the number of locally invasive odontogenic infections requiring hospital care has been observed in many countries. It is more difficult to estimate the incidence of systemic odontogenic infections as these patients typically present at various Emergency Departments lacking understanding of oral diseases. Therefore, the dental source of the systemic infection is often missed. Source control is the cornerstone of managing all infections.
Detection of a microbe potentially of oral origin should prompt dental assessment and clearance of the source if required. Therefore, the microbiology laboratory has an important role in detecting odontogenic infections and guiding clinical care. Also, antimicrobial resistance of oral microbes is one contributing factor for the increase in the incidence of severe odontogenic infections. Appropriate microbiological diagnostics of oral samples is an important tool in antibiotic stewardship. The aim of this session is to update the participants on the epidemiology of odontogenic infections and the role of microbiological diagnostics in dentistry.
Sponsored by Eurobio Scientific
Speakers
Dr Riina Richardson
Challenges in diagnosis and management of a case of COVID-associated pulmonary Aspergillosis (CAPA) on an intensive care unit
Challenges in diagnosis and management of a case of COVID-associated pulmonary Aspergillosis (CAPA) on an intensive care unit
Medical Microbiology
Abstract
Invasive Pulmonary Aspergillosis (IPA) is typically seen in patients who are immunosuppressed, with prolonged or profound neutropenia being the greatest risk factor. In recent years, there have been increasing reports globally of critical care patients developing IPA, particularly following severe Influenza infection. Early during the COVID-19 pandemic, cases of Post-COVID Aspergillosis (CAPA) in intensive care patients began to be reported in the literature, and CAPA is now a well-recognised complication of severe COVID-19 infection. One of the difficulties of diagnosing CAPA in intensive care patients is the lack of diagnostic criteria for IPA in patients without traditional host factors, alongside a lack of clinical suspicion.
This presentation describes the challenges in the diagnosis and management of a case of fatal COVID-19 associated pulmonary Aspergillosis in a patient on intensive care. The current literature on the risk factors, diagnosis, case definition and management of CAPA in intensive care patients will also be reviewed.
Sponsored by Eurobio Scientific
Improving training in parasitology
Point-of-Care Testing
POCT in pathology networks
How COVID-19 has accelerated the POCT landscape
POCT: Benefit to users and practical outcomes for patients
POCT in the anticoagulant service
POCT in the anticoagulant service
Point-Of-Care Testing
Abstract
The anticoagulation department at Blackpool Teaching Hospitals currently serves approx. 4000 warfarin patients in the local areas of Blackpool , Fylde and Wyre. The department runs a full POCT INR testing and warfarin dosing service in a number of community based clinics and has a large domiciliary service which is also runs using full POCT testing. In addition to this the service runs a POCT patient self-testing service with approx. 100 patients, and a drive through service both of which which have proved really useful over the pandemic period.
The service is fully run by Biomedical Scientist Staff and a team of Medical Laboratory Assistants. All INR testing is performed using Roche Coaguchek Pro II devices, linked to Cobas infinity Data Management System. Warfarin dosing is done real time at the community clinics using Dawn AC dosing management system and we currently do in the region of 250 INR tests and warfarin doses per day. The department is currently piloting a new bi-directional interface between Dawn AC and Cobas Infinity, this will allow INR results generated by the Coaguchek Pro II devices to transfer real time into the patient dosing record on Dawn AC. This is going to significantly reduce transcription errors and will allow staff to access and dose patients as results come off the POCT devices and transfer real time electronically to the patient dosing record. This is a new pilot project, and our future hope is to introduce cloud technology to allow real time remote dosing on domiciliary visits.
Our self-testing service has been extremely successful, and patients use the Coaguchek INRange devices allowing us to train patients safely on POCT INR testing and to allow them to test from home and ring results through our virtual Self-Test Clinics . The POCT based nature of the equipment we use, and our service model has allowed the department to adapt and change rapidly over the pandemic even facilitating drive through INR testing using mobile units and mobiles homes during the pandemic. We hope to share our current model and the benefits of POCT testing in an anticoagulation service and how the equipment, data management system and our anticoagulation software helps us to work towards the ISO 15189/22870 standards and increases our patient safety and also patient experience here at Blackpool.
Sponsored by
Speakers
Beverley Straker-Bennett
Leanne Cross
Implementing and managing quality control in a multi-professional POCT team
CEP in POCT – value of the qualification
Teaching and training of POCT for non-laboratory staff
Teaching and training of POCT for non-laboratory staff
Point-Of-Care Testing
Abstract
Knowledge and understanding of point of care testing (POCT) is now embedded into the undergraduate curriculum of all Biomedical Science degree programmes. However, most users of POCTs are non-laboratory staff and this includes professional registered nurses, for which most POC education occurs post-registration in variable and often ad-hoc ways, dependent on needs at the time.
Alongside device specific skills, there is an important unmet need to embed knowledge and understanding of POCT into relevant undergraduate healthcare professional programmes, to align to NHS long term plans for future workforce and use of technological advancement and support pathology services.
This session discusses a POCT curriculum introduced into the pre-registration undergraduate nursing degree programmes at the University of Sunderland, guided by regional POC Biomedical Science leads. It will discuss the project from conceptualisation to impact on the future POCT workforce, the quality of services provided and the Biomedical Scientists supporting it.
Sponsored by
Speakers
Michelle Payne
Quality Management
ISO15189 it’s all about the patient: What to expect from the new version
ISO15189 it’s all about the patient: What to expect from the new version
Quality Management
Learning outcomes
ISO15189 has been the mainstay of pathology accreditation globally and has entered a review period. The purpose of the standard is not actually as an accrediting document, but as a guide to the minimum requirements for competence and quality in medical laboratories.
This session will describe the progress made in the updated version, including why it is being updated as well as an indication on what to expect from the new version as well as the plans to support medical laboratories in the adopted and roll out. A good example of one of the changes is that point of care testing will now be part of the main standard once it is released.
Sponsored by Eurobio Scientific
Speakers
Dr David Ricketts DBMS CSci FIBMS
Quality for the patient, not just for the sake of it
Quality for the patient, not just for the sake of it
Quality Management
Abstract
This talk will explore what value quality activities have on our patients and user experience, and why, when performed correctly, can assist us to improve our service, the patient experience and maybe even free up time…
Sponsored by Eurobio Scientific
Learning from excellence - recognising when things go right
Investigation of serious incidents – what to do when things go wrong
Ensuring quality in an emergency situation
Maintaining a permanent state of readiness
Maintaining a permanent state of readiness
Quality Management
Abstract
Over the last few decades, development of quality management systems and accreditation within healthcare laboratories has moved forward with enormous strides, in part driven by the introduction of Quality Managers in the last iteration of the CPA standards, and then with the merger of CPA with UKAS, the transition of laboratories from CPA to ISO 15189:2012. Regular assessment to ensure conformity with ISO15189:2012 is paramount to keep the momentum and drive to maintain a quality management system that is fit for purpose, but this must also be tempered with an understanding of overall risk.
This session explores the considerations that the quality management teams within the laboratory service need to address in order to keep the quality management system operating effectively, such that it can react to change, respond to situations and extraordinary events (e.g. responses to pandemics), and also to allay stresses or fears of external assessment teams arriving at short notice.
Revision of the foundations of quality management systems and good practice will be outlined, as well as why we have to do what we do as a quality management team will also be presented.
Sponsored by Eurobio Scientific
Speakers
John Ringrow
Remote auditing
Remote auditing
Quality Management
Abstract
We have all been part of a necessary transition in the last few years from a system of onsite assessment to a system that in the majority uses remote assessment for ISO 15189. This has subsequently transformed how assessments are performed. It has to be recognised that this has been a significant undertaking for all involved which has presented both significant challenges and potential benefits. There is need to reflect on these and identify what future benefits maybe gained through remote assessment.
I will present opinions and comments from Laboratory Managers, Quality Managers, Technical Assessors and Assessment Managers. As we progress to potentially a more blended and risk based approach to ISO 15189 assessment and accreditation, we need to be clear where the tool of remote assessment is applicable, what its future role and how laboratories and UKAS should best use this tool.
Sponsored by Eurobio Scientific
ISO 15189 it’s all about the patient: What to expect from the new version
ISO 15189 it’s all about the patient: What to expect from the new version
Quality Management
Learning outcomes
ISO15189 has been the mainstay of pathology accreditation globally and has entered a review period. The purpose of the standard is not actually as an accrediting document, but as a guide to the minimum requirements for competence and quality in medical laboratories.
This session will describe the progress made in the updated version, including why it is being updated as well as an indication on what to expect from the new version as well as the plans to support medical laboratories in the adopted and roll out. A good example of one of the changes is that point of care testing will now be part of the main standard once it is released.
Sponsored by Eurobio Scientific
Speakers
Dr David Ricketts DBMS CSci FIBMS
Quality for the patient, not just for the sake of it
Learning from excellence - recognising when things go right
Investigation of serious incidents – what to do when things go wrong
Maintaining quality while working from home
Maintaining quality while working from home
Quality Management
Abstract
The news of the global Covid-19 pandemic breaks and I am a few months post op from major surgery. I am planning my return to work and receive communication that I have to shield. Having been a multidisciplinary Quality Manager for 7 years I have always felt that to maintain the quality culture in the workplace, I should be visible to staff.
In this presentation I will talk about the challenges I faced to maintain the Quality agenda and undertake UKAS remote assessment. From the perspective of my colleagues….how did they adapt to me not being on site? On reflection was it an effective way of working?
Sponsored by Eurobio Scientific
Ensuring quality in an emergency situation
Remote auditing
Remote auditing
Quality Management
Abstract
We have all been part of a necessary transition in the last few years from a system of onsite assessment to a system that in the majority uses remote assessment for ISO 15189. This has subsequently transformed how assessments are performed. It has to be recognised that this has been a significant undertaking for all involved which has presented both significant challenges and potential benefits. There is need to reflect on these and identify what future benefits maybe gained through remote assessment.
I will present opinions and comments from Laboratory Managers, Quality Managers, Technical Assessors and Assessment Managers. As we progress to potentially a more blended and risk based approach to ISO 15189 assessment and accreditation, we need to be clear where the tool of remote assessment is applicable, what its future role and how laboratories and UKAS should best use this tool.
Sponsored by Eurobio Scientific
Patient results – are they as accurate as they can be?
Transfusion Science
Ensuring continuity of the blood supply to English hospitals during the COVID-19 pandemic
Introduction of a new blood component
Introduction of a new blood component
Transfusion Science
Learning outcomes
Delegates attending this presentation will gain an understanding of:
- The key drivers for change and the requirements for new blood components.
- The process for the introduction of a new component:
Phase 0 studies > SACBC review > SACIT component codes > Phase1 studies with/without a clinical trial.
Abstract
Blood has been used for the treatment of patients for more than 200 years and thankfully since Dr James Blundell carried out the first transfusion of human blood for the treatment of haemorrhage a lot has changed, making transfusions today significantly safer now, than they were in the 1800s.
What has been the biggest change in the field of transfusion over this time, is a subject of much debate, but is perhaps the move from the transfusion of fresh whole blood to the manufacture and storage of blood components. This has not only meant that blood is now available on demand but also that patients receive what they need (specific components), rather than what was available (whole blood).
The introduction of a new blood component in the 21st Century takes considerable effort and resources to ensure that they are of good quality, safe and effective in patients meeting the requirements of regulators. In the UK, the introduction of new blood components is standardised by the Guidelines for Blood Transfusion Services in the United Kingdom, or the red book but ultimately it is the Medicines and Healthcare products Regulatory Agency (MHRA) that is ultimately responsible for ensuring that blood components ‘work’ and are acceptably safe.
Speakers
Michael Wiltshire
Major Haemorrhage - a laboratory perspective
Major Haemorrhage - a laboratory perspective
Transfusion Science
Abstract
Effective management of major haemorrhage is an important part of Hospital Transfusion life. It’s widely agreed that success relies on good communication, early recognition and intervention in the clinical setting to ensure patient survival.
Successful management of major haemorrhage requires a protocol driven multidisciplinary team approach. In this talk "Major Haemorrhage - a Laboratory Perspective" we explore major haemorrhage from the Biomedical Scientist point of view. We will specifically look at the Major Haemorrhage Policy from the Newcastle Trust and discuss some of the challenges the laboratory face, particularly in terms of staff experience and training.
The talk concludes with a case study examining 24 hours working in the laboratory with examples of multiple haemorrhage activations and how the laboratory was able to successfully manage the difficult situation whilst continuing to provide a routine Transfusion service.
Speakers
Caroline Swales
How electronic requesting systems for blood products like ICE could be utilised to reduce incidences of TACO
Blood group – Kidd
Blood group – Kidd
Transfusion Science
Learning outcomes
Delegates attending this presentation will:
- Increase their knowledge of the Kidd blood group system antibodies and antigens
- Learn about the functions of Kidd antigens
- Appreciate the relationship between Kidd blood group antibodies and transfusion reactions
Speakers
Martin Maley
International Blood Group Reference Laboratory (IBGRL) – finding new blood group antigens
Antibody workshop, IBMS Transfusion Science Specialist Advisory Panel
Antibody workshop, IBMS Transfusion Science Specialist Advisory Panel
Transfusion Science
Abstract
Join us at one of our lunchtime sessions where we will be hosting an antibody workshop. We will be looking at different types of antibodies, how to positively identify or eliminate any suspected clinically significant antibodies, whilst testing your knowledge and skills. Our aim to make the session fun and interactive, focusing on some top tips for solving those antibody mysteries.
Speakers
Jill Caulfield
Martin Maley
Column agglutination technology
Column agglutination technology
Transfusion Science
Learning outcomes
This presentation will give the delegate:
- An overview of Column Agglutination technology - how it works and how it is applied in the Transfusion laboratory
- An appreciation of the advantages and disadvantages of Column Agglutination technology
- Information on the future developments.
Speakers
Kerry Dowling
Microarray technology
Microarray technology
Transfusion Science
Learning outcomes
Delegates attending this presentation will:
- Understand how Microarray technology works and how it is applied in the Transfusion laboratory
- Understand the advantages and disadvantages of Microarray technology
- Learn about the future developments
Abstract
Microarray technology can provide a method for performing highly multiplexed immunoassays. Whilst the technology was first developed for DNA microarrays, so called protein microarrays have been developed that can perform conventional immunoassays in a rapid, miniaturised and multiplexed way.
Automated ABO and RhD typing are routinely performed on donor and patient samples as part of pre-transfusion testing, while additional testing is often required to do extended antigen typing and Direct Antiglobulin Testing (DAT). A platform that could provide ABO/Rh, antibody screening/identification, extended blood types and DAT results in one comprehensive single-step test would offer significant advantages in the provision of blood for patients. Quotient are developing a serology-based microarray technology platform. This platform has the capability to perform comprehensive blood group typing, antibody identification and DAT in parallel using one sample.
The different formats of microarrays available will be discussed as an overview, then the Quotient MosaiQ System will be discussed as an example, showing the menu and components of the product, the assay steps and results analysis as well as outline the main features of the system instrument.
Speakers
Dr Janine Robb
The Cambridge Cellular Therapy Laboratory
The Cambridge Cellular Therapy Laboratory
Transfusion Science
Learning outcomes
Delegates attending this presentation will learn:
- What is a therapeutic tissue laboratory
- Clinical uses of tissue laboratory products
- Who works in such a laboratory.
Abstract
The Cambridge Cellular Therapy Laboratory (CCTL) a busy and progressive HTA and JACIE accredited Regional Laboratory at Addenbrooke’s Hospital, Cambridge University Hospitals (CUH) NHS Foundation Trust. CCTL is based on the Cambridge Biomedical Campus, the largest Biomedical Research campus in Europe; home to two NHS flagship trusts, multiple world-class research institutes, the University of Cambridge Medical School and a thriving biopharma ecosystem.
CCTL is the campus sole GMP facility and is responsible for supporting the Transplant Programmes in the East of England; the Cambridge Haematopoietic Stem Cell Transplant Programme (including the Ipswich Unit) and the Norwich Transplant Programme.
The heart of the CCTL service is delivering cellular therapies, including providing testing, processing, cryopreservation and storage of cells to treat patients with haematological malignancies. CCTL will expand to a new purpose built facility within the campus Jeffrey Cheah Biomedical Centre; this will provide 4 Grade B clean rooms each with independent air handling with capability to manage Class 1 and Class 2 GMOs.
The CCTL along with the clinical transplant programmes is increasingly involved in Immune Effector Cell and cellular AT(I)MP handling. CUH has been designated by NHS England as a provider for chimeric antigen receptor T cell (CAR-T) therapy, and is integrally involved in clinical trials in melanoma, lung cancer and haematological malignancies.
Speakers
Sarah Albon
Network development – staffing issues
Network development – staffing issues
Transfusion Science
Learning outcomes
Delegates attending this presentation will have an understand the:
- Impact of networks on Pathology
- Specific issues of networks on transfusion
- Staffing solutions to ensure successful network implementation
Abstract
With the consolidation of pathology services across the country it's important to look at how staff within transfusion departments are being affected by changes, and to understand the importance of correctly capacity planning so everyone is able to fulfill their job roles.
Improving standards of service, safety and patient care in a network can only occur where there is a psychologically safe environment that allows colleagues to openly question poor staffing levels so improvements can be made. This presentation will give ideas on how to format capacity plans.
Speakers
Rashmi Rook
Major haemorrhage protocols
Major haemorrhage protocols
Transfusion Science
Learning outcomes
Delegates will learn
- What a bleeding trauma looks like
- How does A/E deal with bleeding trauma
- Why are major haemorrhage protocols important
- How are these protocols evolving.
Abstract
Major Haemorrhage Protocols help facilitate rapid access to blood products, but are more often used in theatre and Emergency Department locations. Advanced in the military and adapted to NHS civilian care, they vary from site to site and lead to non-parity in care. The presentation will provide examples of how care is delivered with and without MHP use, some background evidence on why implementation is of benefit, and targets to be delivered. The presentation will review an example protocol and how this has been adapted and reviewed in a Major Trauma Centre.
Speakers
Dr Ric Proctor
Laboratory errors in transfusion
Laboratory errors in transfusion
Transfusion Science
Learning outcomes
Through the discussion of case studies of laboratory errors delegates attending this presentation will:
- Learn about the types of errors generated within the laboratory.
- Understand the root causes of errors.
- Improve knowledge on how to mitigate against laboratory error.
Abstract
Serious Hazards of Transfusion (SHOT) is the United Kingdom independent, professionally-led haemovigilance scheme which has been collecting and analysing anonymised information on adverse events and reactions related to blood transfusion from all healthcare organisations involved in the transfusion of blood components in the United Kingdom since 1996.
The submitted reports are analysed and collated into an annual report which includes key messages, learning outcomes and recommendations that can be acted upon by the reporting organisation to improve patient safety.
The presentation will cover key highlights and safety messages from review of the laboratory errors submitted to SHOT including effective incident investigation and human factors principles.
Speakers
Dr Shruthi Narayan
Antibody workshop, IBMS Transfusion Science Specialist Advisory Panel
Antibody workshop, IBMS Transfusion Science Specialist Advisory Panel
Transfusion Science
Abstract
Join us at one of our lunchtime sessions where we will be hosting an antibody workshop. We will be looking at different types of antibodies, how to positively identify or eliminate any suspected clinically significant antibodies, whilst testing your knowledge and skills. Our aim to make the session fun and interactive, focusing on some top tips for solving those antibody mysteries.
Speakers
Jill Caulfield
Martin Maley
Virology
New strategies for new diseases – capacity building
New strategies for new diseases – capacity building
Virology
Learning outcomes
This presentation will:
- Discuss strategies for increasing capacity in response to new viral diseases in the UK.
- Reflect on the lessons learned and shared from recent pandemic responses.
- Assess challenges to capacity building and options for the mitigation of those.
Sponsored by
New strategies for new diseases – crowdsourcing to resolve problems
Pandemic response – from zero to 1 million tests a day. Innovation, lessons learned and legacy
Pandemic response – from zero to 1 million tests a day. Innovation, lessons learned and legacy
Virology
Learning outcomes
Delegates attending this presentation will:
- Broaden knowledge of SARS-COV-2 detection technologies from PCR to breath tests and sniffer dogs
- Gain wider insight into the Test and Trace technical and operational response and the lasting legacy
- Understand how horizon scanning influenced the diagnostic pandemic response, from testing technologies to service provision
- Be able to reflect and ask unanswered questions and share the lessons learnt
Sponsored by:
Pandemic response – impact on vaccination programme and virus resurgence
Pandemic response – impact on vaccination programme and virus resurgence
Virology
Abstract
The UK routine immunisation programme is a complex schedule offering protection against more than ten different viruses, and is delivered by a range of different health care providers to individuals at all stages of life. The COVID pandemic has led to disruptions to many of these services with consequent drop in vaccine uptake. However, over the same time period the increase in social distancing and reduction in social mixing has led to drops in the incidence of many infectious diseases.
The presentation will review the effect of the pandemic on vaccine uptake against many key viruses, and the effect on virus circulation in the general population. In addition, the role of the newly introduced COVID vaccine programme will be discussed, it’s effect on the other vaccine programmes, as well as the control of COVID infections including Omicron.
Sponsored by
Pandemic response and impact – economic impact on research and scientific development
Pandemic response and impact – economic impact on research and scientific development
Virology
Learning outcomes
This talk will take a look into how research funding has changed as the result of the pandemic. We will explore the immediate challenges and opportunities presented to scientists in funding their research. Looking to the future, how will funding within scientific research change going forwards.
Sponsored by
Caring for the UKs first COVID-19 patients
The June Almeida COVID-19 laboratory set up: lessons learnt
The June Almeida COVID-19 laboratory set up: lessons learnt
Virology
Learning outcomes
Delegates attending this presentation will learn:
- Factors which need to be considered when setting up a laboratory.
- How approach implementation of testing protocols, procurement of reagents and equipment and staff recruitment and training in the context of increasing Covid-19 testing capacity during 2020 and 2021.
- Lessons learned after reflection and review on issues including quality management, recruitment, training, procurement.
Abstract
June Almeida made the discovery of coronavirus in 1964, working as a virologist in St Thomas’. Covid-19 is a new coronavirus in the same family first discovered by June, who helped pioneer virus imaging. The lab has been set up to help increase testing for patients, staff, and the general population.
Since the start of the COVID-19 pandemic, the Department of Health and Social Care has vastly expanded the nation’s testing capacity, by doubling the capacity of the NHS and Public Health England laboratories as well as setting up an entirely new nationwide network of testing sites and new Lighthouse Laboratories and partner laboratories to process COVID-19 swab samples.
The June Almeida Initiative (JAL) is a high throughput facility, set up as a collaboration between King’s College London and Viapath, and is dedicated to providing COVID-19 pillar two testing for the National Testing Programme.
Looking back at the set up the June Almeida Lab, Waterloo, London, set up in response to increase Covid-19 testing capacity for pillar 11 samples. Lessons learned to include, what has worked well and areas of improvement. On issues surrounding Quality, recruitment, training, procurement etc.
Sponsored by Qiagen
Speakers
Bamidele Farinre FIBMS, MSc, BSc
Hepatitis C - West Midlands Test & Treat Roadshow
Hepatitis C - West Midlands Test & Treat Roadshow
Virology
Abstract
The Test and Treat Roadshow was set up to address some of the many barriers that people face when seeking access to care. The target group for the roadshow was primarily people who were injecting drug users – and mostly those who were actively using. The people targeted were usually not accessing substance misuse services and the majority were homeless with a high number who had very high ‘did not attend’ (DNA) rates for hepatitis C care appointments.
With this target group, there were a host of hurdles that the project needed to overcome. Often, PWID and those who are homeless find it difficult to engage with care services that require travelling to secondary locations or accessing care over a period of time in separate instances. It was imperative that the roadshow delivered testing, treatment, medication and follow-up in the most easily accessible format possible.
The roadshow sought to create a ’Test & Treat’ service which could be completed in two visits, with the van travelling to service users so there would not be a need for them to travel. The service operated on a ‘walk-in’ basis so there was no need for appointments, and RNA results were provided within one hour following an antibody positive result. The full course of medication, following a positive result, were given on a second follow up visit to the van.
Sponsored by Qiagen
Speakers
Phillip Bonnet
Outbreak controls: Tattoo and Piercing Infection Cases
Outbreak controls: Tattoo and Piercing Infection Cases
Virology
Abstract
The UKHSA Food, Water and Environmental Microbiology Laboratories deal largely with food and water-borne public health infection issues, however here risks associated with a more niche area, tattooing and piercing, are presented. The demand for tattoos and piercings has increased in recent years resulting in an increase in premises offering these procedures.
Regulation of these businesses requires application for a licence but does not require any medical training or qualifications for staff. The presentation shows examples of infections resulting from these procedures and results of environmental sampling surveys from tattooing and piercing establishments. The presentation focusses on bacteriological infections but also points at the risks and risk factors of viral infections.
Sponsored by Qiagen
Speakers
Deborah Fenelon
COVID-19 - local outbreak control
Outbreak control: Value of epidemiology & whole-genome sequencing
Outbreak control: Value of epidemiology & whole-genome sequencing
Virology
Learning outcomes
Delegates attending this presentation will learn:
- How to interpret whole genome sequencing (WGS) data
- Use of epidemiological data in combination with WGS data in outbreak management to infer relatedness & identify transmission networks
- Pros & cons of using WGS data for outbreaks
- How WGS and epidemiology can support use of Public health measures in outbreak management
Abstract
Background
Understanding transmission chains in real-time is essential to ensure outbreak mitigations are implemented rapidly, hypotheses are tested, and the outbreak effectively managed to reduce onward transmission of SARS-CoV-2. We present epidemiological and whole genome sequencing (WGS) data for two different incidents. A small hospital-based SARS-CoV-2 incident linked to a variant under investigation (VUI-21JAN-01) and a citywide incident. We will describe the epidemiological and WGS findings in these two settings.
Methods
SARS-CoV-2 PCR testing data routinely collected through national surveillance systems was enriched with epidemiological information obtained through local public health investigations. Analysis was carried out by the Field Service South West Team (UKHSA) and these data were supplemented, where possible, with WGS sequence analysis carried out by the national Genomics Cell (UKHSA).
Results
Real-time situation reports (sitreps) were provided to multiple stakeholders in these two investigations and established transmission trends over time. Public health control measures varied by setting an were implemented to reduce transmission, with decision making informed by these outputs.
For incident 1
WGS and epidemiological analyses identified a small cluster of 6 confirmed and 5 probable cases of COVID-19 VUI-21JAN-01 (P2 variant). 55% (6/11) of cases in this cluster worked in hospital A and 5/11 cases were epidemiologically linked (household members) to a confirmed case that did work at Hospital A.
For incident 2
The majority of cases with WGS data (63/68) fell within a single large genomic cluster which contained employees from a single workplace, their contacts, other known workplace clusters and the majority of the cryptic origin cases that were sequenced. This finding supported the suspected transmission between employees and to their disclosed contacts.
Conclusions
Through early analysis of epidemiological data, enriched by WGS information we can focus control measures and mitigations more effectively and test hypotheses to understand what is driving the transmission during outbreaks of SARS-CoV-2.
Sponsored by Qiagen
Speakers
Derren Ready
Viral infections in risk groups – infections in pregnancy
Viral infections in risk groups – infections in pregnancy
Virology
Abstract
The objectives of the talk are:
- To provide an overview of infections in pregnancy, and their impact on the health of the mother and baby.
- To consider the approach to, and complexities of, diagnostic testing.
- To highlight the importance of considering syphilis infection later in pregnancy.
- To focus on congenital cytomegalovirus infections, including an update on recent evidence relating to its management and the importance of early diagnosis.
Sponsored by Qiagen
Speakers
Dr Sheila Waugh MBChB, BSc, PhD, MRCPCH, FRCPath
Viral infections in risk groups – infections in childhood
Viral infections in risk groups – infections in prisons
Viral infections in risk groups – infections in prisons
Virology
Abstract
As part of the worldwide initiative to eradicate Hepatitis C Virus (HCV) by 2030, everyone living with HCV needs to be diagnosed and treated in a bid to reduce the pool of infection to as near as zero as is practicably possible and stop new infections and re-infections occurring. Prisons are central to this initiative. Nearly a third of people in prison have injected drugs and almost half of people who inject drugs in England have HCV. However, historically very few people entering prison or serving sentences have been offered tests and very few have received treatment. Prisons present a unique opportunity to test this high-risk group, ensuring people living with hepatitis C are diagnosed and enter a care pathway so they can be treated and cured.
In 2017, the seven major prisons in the North East of England began screening for blood borne viruses on all new admissions to the prisons, however it quickly became apparent that the existing population were not being offered testing and a pool of infection was still identifiable within the prisons. We, therefore, instigated a High Intensity Test and Treat (HITT) plan. This involved going into a prison and testing all residents for blood borne viruses. The initial HITT took place at HMP Low Newton and 99% of prisoners accepted BBV testing of which 32% were found to be HCV antibody positive. This presentation will take a look at the organisation required and the results achieved.
Sponsored by Qiagen
Hepatitis C - elimination of a treatable pandemic. Where are we now?
Hepatitis C - elimination of a treatable pandemic. Where are we now?
Virology
Learning outcomes
Delegates will learn about the:
- Current management of hepatitis C
- Current diagnostic pathways
- Novel ways of diagnosing at risk individuals from marginalised communities
- What part can the laboratory play in achieving elimination
- Use and deployment of point of care testing in Hepatitis C
Abstract
In 2016, the WHO Global Health Sector Strategy (GHSS) on viral hepatitis provided the initial roadmap for the elimination of viral hepatitis as a public health problem by 2030. Since then countries have developed programs designed to achieve elimination. There are several challenges that health providers face in delivering elimination including (broadly) identifying and carrying out testing of at risk populations, linkage to care, compliance and completion of treatment, obtaining test of cure, proving successful elimination and finally maintaining that status.
In this talk I will discuss the challenges experienced both at ground level and from an organisational level and discuss novel strategies developed to help achieve elimination.
Sponsored by Qiagen
Speakers
Dr Brendan Healy
Prospects for the reduction of human rabies cases by 2030
Prospects for the reduction of human rabies cases by 2030
Virology
Abstract
Rabies is a life-threatening neglected disease: thousands of cases are reported annually in endemic countries, although the actual numbers are probably grossly underestimated. Rabies is a zoonotic disease that is caused by infection with viruses of the Lyssavirus genus, which are transmitted via the saliva of an infected animal. Dogs are the most important reservoir for rabies and dog bites account for > 99% of human cases.
The virus first infects peripheral motor neurons and symptoms occur after the virus reaches the CNS and replicates. Once clinical disease develops; it is almost certainly fatal. Primary prevention involves dog vaccination campaigns to reduce the virus reservoir. If exposure occurs, timely post-exposure prophylaxis can prevent the progression to clinical disease and involves appropriate wound care, the administration of rabies immunoglobulins and vaccination. Rabies control is a dynamic field. The progress that has been made in Europe and North America in successfully eliminating dog-mediated human rabies is being transferred to countries in Asia and Africa. Rabies National Control Programmes are being used in a regional context ensuring these countries remain on track to eliminate human rabies transmitted by dogs by 2030.
A multifaceted approach for human rabies eradication that involves government support, disease awareness, vaccination of at-risk human populations and, most importantly, dog rabies control, is necessary to achieve the goal of reducing the number of cases of dog-mediated human rabies to zero by 2030. The vision for a world free of human rabies is aligned with the Sustainable Development Goals to combat poverty, hunger, and disease. The dog-mediated human rabies eradication endgame poses a diverse set of challenges in the 21st century. Eliminating the disease in animals and in so doing, preventing human cases would be an unprecedented achievement and rabies would be the first zoonotic viral disease to be globally eradicated.
Sponsored by Qiagen
Speakers
Professor Anthony Fooks
Water quality and public health - tracking human viruses in the aquatic environment
Water quality and public health - tracking human viruses in the aquatic environment
Virology
Abstract
Many human viruses, including enteric (e.g. enteroviruses, noroviruses) and respiratory (SARS-CoV-2, influenza viruses) pathogens, are shed in the faeces and urine of infected individuals. As the decay of these viruses and/or their genetic material is slow, the viruses can be detected in sewage.
Using qPCR and sequencing, viral gene fragments can be quantified and the variants circulating in the communities can be described. Thus, wastewater-based epidemiology (WBE) has been implemented worldwide, enabling SARS-CoV-2 surveillance during the COVID-19 pandemic. In the UK, approximately 80% of the population is covered with sampling conducted at municipal wastewater treatment plants, within-network sites, quarantine hotels, student halls, assisted living homes, etc.
The data obtained are now routinely implemented in decision making on the mitigation of the COVID-19, highlighting the usefulness of WBE and providing the opportunity to investigate other pathogens and chemicals (informing on the health and wellbeing of the population) in wastewater.
Furthermore, there are many viruses, mostly enteric pathogens, which can survive the wastewater treatment process and persist in the sewage-exposed aquatic environment for long periods of time. These viruses can pollute bathing water bodies and can bioaccumulate in bivalve shellfish and are associated with water and foodborne illnesses.
The survival and transport patterns of these pathogens are not well-understood due to the lack of reliable methods which can be implemented in environmental studies. With recent developments in in vitro culturing, molecular integrity assays and biosensor technology, coupled with mathematical modelling and machine learning approaches, the fate of these viruses in the aquatic environment can be explored and further outbreaks may be prevented.
Sponsored by
Update to enterovirus infections
Transfusion and Transplantation – Update on testing strategies
Transfusion and Transplantation – Update on testing strategies
Virology
Learning outcomes
This session will cover:
- An overview of testing strategies within NHSBT
- Mandatory and additional screening of donors/donations
- The differences between mandatory screening requirments for blood donation and for tissue and stem cell donation
Sponsored by Qiagen
Speakers
Victoria Maddox
Microbiological safety of organs for transplantation – assessing the risk–benefit balance
Microbiological safety of organs for transplantation – assessing the risk–benefit balance
Virology
Learning outcomes
This presentation will understand:
- The rationale of donor screening.
- What can and cannot be tested for.
- The importance of contextual result interpretation by specialists.
- Rapid response to emerging threats.
- Learning from transmission events.
Abstract
Detailed donor characterisation is a fundamental tool that helps maintaining safety and quality of organs and tissues for transplantation. Although only one of many steps, infectious diseases screening is an important part of the assessment process; given the time constraints and limited information available, some challenges are very specific to the deceased organ donation scenario, which the presentation will concentrate on. Risk of disease transmission to transplant recipients must be kept to a minimum, but assessment of risk-benefit can only be done on a case by case, with decisions made jointly by the transplant teams and their patients.
It is important that microbiologists and virologists understand the guiding principles of organ donation and transplantation in order to maximise our crucial contribution towards increased utilisation of organs for transplantation.
Sponsored by
Speakers
Dr Ines Ushiro-Lumb
Transplantation – virology clinical case studies
Transplantation – virology clinical case studies
Virology
Learning outcomes
Through the discussion of clinical case studies delegates will:
- Gain insight into virology infections in transplant patients.
- Understand the role of laboratory investigations in the clinical management of transplant patients.
- Learn about specific clinical cases at a specialist referral transplant hospital.
Abstract
A series of cases will be used to illustrate the range of viral infections that have affected cardiothoracic transplant recipients in our centre over the last few years. Rather than focusing on respiratory pathogens such as SARS-CoV2, we will look at less common viral infections such as Parvovirus B19 and Human Herpes Virus 8 that may affect immunosuppressed individuals. The cases will explore challenges in diagnosis, laboratory investigation and management.
Sponsored by
Speakers
Dr Stephen Pettit
Vaccine hesitancy – causes and effects
Vaccine hesitancy – causes and effects
Virology
Abstract
Vaccine hesitancy has been described since the time of Edward Jenner but has become much more high profile over past 18 months. The causes of hesitancy are multifactorial and complex and a better understanding will allow the development of better support for vaccine uptake.
In this presentation I will consider different causes that include the 3C model described by the World Health Organisation as well as socio-political reasons. This will be followed by a discussion of the advantages and disadvantages of the measures that can be taken to support vaccine uptake.
Sponsored by
Speakers
Dr Rajeka Lazarus
Vaccine development and production
Vaccine development and production
Virology
Abstract
Prior to the Covid pandemic the use of viral vectors for either therapeutic or vaccination uses had been largely focused on the treatment of rare diseases including Zolgensma for treatment of spinal muscular atrophy (SMA) the most expensive drug produced to date at $2.1m/dose, and the only licenced vaccine was against Ebola in December 2019. However despite the limited number of licenced products the use of viral vectors for gene therapy has attracted multibillion dollar investments into both product and manufacturing development. On the back of these investments has come the successful development of Covid vaccines by the Jenner Institute in Oxford, Janssen Biologics and the Gamaleya National Research Centre in Moscow amongst others, and production of over 2bn does of these vaccines which have now become a critical part in the global vaccination strategies against Covid 19.
This presentation will look at the background of the development and use of viral vaccines as both therapeutic entities and as vaccines, the associated manufacturing process and the challenges in producing these products at industrial scale including the associated analytics required to support their clinical use.
Sponsored by
Speakers
Tony Hitchcock
Virus Vaccines - SARS-CoV-2 vaccines – a regional perspective
Virus Vaccines - SARS-CoV-2 vaccines – a regional perspective
Virology
Learning outcomes
Delegates attending this presentation will gain an insight into and have a greater understanding of:
- A regional SARS-CoV-2 vaccination programme as part of pandemic response.
- The data analysis undertaken to inform successes and challenges faced within such a programme.
- The reasons behind inequalities in uptake between groups for SARS-CoV-2 vaccination & how these can be addressed.
Abstract
The unprecedented challenges of the covid-19 vaccination programme rollout came alongside unprecedented availability of data and insights to guide and target service delivery. This talk will outline what we know about inequalities in covid vaccine uptake between different groups of people, strengths and limitations of our data and what has been done on the ground to design and deliver an equitable service, with a view to taking these insights forward into other NHS services.
This talk will also consider the public health and behavioural science frameworks that can explain why some people choose or choose not to be vaccinated, and the wider determinants of all health for populations.
Sponsored by
Speakers
Dr Eleanor Powers
UKAS
Pathology GIRFT: Next steps and implementing the recommendations
Pathology GIRFT: Next steps and implementing the recommendations
UKAS
Abstract
The NHSI Getting It Right First Time (GIRFT) is a clinically-lead, evidence-based quality initiative to identify, and address, unwarranted variation in the service; there are over 40 clinical work streams, including Pathology. The GIRFT process includes:
- Gathering data on a variety of metrics and activities.
- Producing a Data-Pack for each trust, where their processes are compared with all other trusts in England.
- Visiting each Trust to have discussions with all stakeholders and “deep-dive” into the data. Good practices are highlighted and an agreed action plan is developed to address unwarranted variation.
- Writing a National Report based on the evidence obtained, the unwarranted variation identified and the experience of the experts.
- The National Report is an evidence-based document highlighting best practices, concerns and a strategy for the future delivery of Pathology. It contains 21 major recommendations (six on Clinical Quality, six on data quality, seven on process quality, and one each on workforce and financial quality).
Multiple stakeholders are required to implement these recommendations, spanning from individual local teams up to National bodies.
The GIRFT team is now working with many groups to ensure that the recommendations are implemented. This process will be based on a change management process based on co-production, where all stakeholders will be able to be part of and implement the recommendations into a system change supported by all.
The GIRFT process is about improving the quality of the service and reducing the unwarranted variation in the service. Harmonisation, and reducing unnecessary processes, will improve the service and reduce unnecessary expenditure- Right Test, Right Place, Right Time.
Sponsored by Abbott
Speakers
UKAS Accreditation to support the pandemic response- Private providers of covid 19 sampling and testing
Optimising UKAS Assessments
Optimising UKAS Assessments
UKAS
Abstract
Alongside much hard work to respond as an Accrediting Body to supporting the Pandemic response, we have also been working on many projects to optimise the assessment process, both for the assessment processes that we use, and to benefit our customers to ensure a mutually beneficial experience and to add value to the customer’s quality management system processes.
We will review the background to these projects, and outline the activities and changes that are be introduced for pre-assessment activities, during the assessment and also post assessment activities. Engagement with your Assessment Manager is key to enable the smooth planning and conduct of assessments, and there are a number of initiatives that will help both us and you throughout the whole process.
In addition, there are other projects and improvements to process that are being piloted, and other influences upon assessments from external sources that will impact upon assessment logistics and what pathology services will look like in the future. These will come to fruition during this year.
Sponsored by Abbott
Speakers
John Ringrow
